Vaccines and Global Health: The Week in Review
21 August 2022 :: Issue 667
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch

Editor’s Note:
Vaccines and Global Health: The Week in Review resumes publication with this edition following annual leave for the Editor.
Milestones, Perspectives

COVID Impacts – Health Systems

Emerging Stronger After COVID-19 - Priorities for Health System Transformation (2022)

A Special Publication from the National Academy of Medicine, 2022

568 pages | 6 x 9 | PAPERBACK
PDF: https://nap.nationalacademies.org/download/26657

In mid-2022, the United States has lost more than 1 million people to the COVID-19 pandemic. We have been real-time witnesses to scores of heroic responses to the disease, death, inequity, and economic strife unleashed by the virus, but have also experienced the consequences of poor pandemic preparedness and long-standing structural failures in our health system.

For decades, the U.S. health system has fallen far short of its potential to support and improve individual and population health. The COVID-19 pandemic has presented death and devastation—but also an unprecedented opportunity to truly transform U.S. health, health care, and health delivery.

To capitalize on this opportunity, the National Academy of Medicine gathered field leaders from across all of the major health system sectors to assess how each sector has responded to the pandemic and the opportunities that exist for health system transformation. The opportunity is now to capitalize on the hard-won lessons of COVID-19 and build a health care system that centers patients, families, and communities; cares for clinicians; supports care systems, public health, and biomedical research to perform at the best of their abilities; applies innovations from digital health and quality, safety, and standards organizations; and encourages health care payers and health product manufacturers and innovators to produce products that benefit all.

This publication has undergone peer review according to procedures established by the National Academy of Medicine (NAM). Publication by the NAM signifies that it is the product of a carefully considered process and is a contribution worthy of public attention, but does not constitute endorsement of conclusions and recommendations by the NAM. The views presented in this publication are those of individual contributors and do not represent formal consensus positions of the authors’ organizations; the NAM; or the National Academies of Sciences, Engineering, and Medicine.

NAM Special Publication on Lessons from COVID-19 Identifies Compelling Needs for Health System Transformation

August 10, 2022

...The NAM Special Publication pulls together the nine NAM Discussion Papers comprehensively assessing the pandemic’s impact on each major health care system sector. Released as they were completed, each sector assessment provided a deep dive into the
experiences of those on the front lines of responding to the pandemic, a summary of key lessons learned from those experiences, and highlights of the system-wide implications. This NAM Special Publication adds a new concluding chapter developed by the lead authors of the sector-specific papers, identifying and underscoring critical system-wide lessons common to all of the sector assessments.

The opportunity is now to capitalize on the hard-won lessons of COVID-19 and build a health care system that centers patients, families, and communities; cares for clinicians; supports care systems, public health, and biomedical research to perform as continuously learning organizations; applies innovations from digital health and quality, safety, and standards organizations; and structures incentives that facilitate the attention and actions of health care payers and health product manufacturers and innovators oriented to whole person and whole population health progress.

Release of this NAM Special Publication will be followed by special initiatives of the multiple sectors of the NAM Leadership Consortium to catalyze progress with particular emphasis on the priorities related to health financing, community and individual engagement, digital health, and accelerated evidence generation. A meeting will be scheduled by NAM in Fall 2022 to review the findings, priorities, and collaborative activities for progress...

::::::

::::::

The Rockefeller Foundation Launches the Vaccination Action Network to Strengthen Health Systems and Scale Up Covid-19 Vaccinations in Sub-Saharan Africa

Amref Health Africa selected as implementing partner to provide technical assistance for the new peer-to-peer learning network Nairobi

Nairobi | August 2, 2022 – The Rockefeller Foundation announces the launch of the Vaccination Action Network (VAN), a USD$7.4 million locally-led, peer-to-peer learning initiative designed to engage public health decision-makers across sub-Saharan Africa and bolster their efforts to strengthen health systems while scaling up Covid-19 vaccine demand strategies.

Sabin Vaccine Institute and Dalberg are the secretariat for the network, while Amref Health Africa (Amref) is playing a key role to guide and administer subgrants to local organizations in participating countries so that they can implement vaccine demand generation strategies discussed during the learning sessions.

The network is already connecting ministry of health officials, implementing partners, and other key actors across Kenya, Malawi, Tanzania, and Uganda through activities designed to take place within and between countries (intra- and cross-country), so participants can share lessons learned and best practices for boosting local demand for Covid-19 vaccines. Plans to expand to other countries in the region are underway as well...

While more than 60 percent of people have been fully vaccinated against Covid-19 globally, just 20 percent of people in Africa have received full doses. Inconsistent and inequitable access to supplies initially hindered the continent’s vaccination campaigns. However, uptake is now primarily impacted by complex delivery scenarios, limited access to vaccination centers, and other ongoing demand barriers, such as vaccine hesitancy and waning concerns about Covid-19 infection.
VAN’s objective is to help decision-makers understand the drivers behind vaccination and support initiatives that will increase Covid-19 vaccine uptake, while strengthening routine immunization so that health systems are better equipped to respond when the next pandemic strikes. This reflects The Rockefeller Foundation’s regional commitment to support localized solutions, empower community representatives, and create more resilient health systems.

“The Vaccination Action Network is helping to establish new channels of communication that will consistently elevate regional learnings, solutions, and leadership,” said William Asiko, Vice President of The Rockefeller Foundation Africa Regional Office. “By making these discussions country-led, we want to create a space where those directly involved in vaccination campaigns are able to voice what is working, what isn’t, and what needs to change to improve vaccination rates.”

Peer-to-peer learning is an important tool for officials who are working to address these challenges. Since the start of the Covid-19 pandemic, this type of intra- and inter-country coordination has helped the continent scale up genomic sequencing and secure essential tools, including personal protective equipment and diagnostic tests.

“By encouraging officials to come together, the Vaccination Action Network is opening new dialogues that emphasize regional solutions to local challenges,” said Githinji Gitahi, Group CEO at Amref. “This is essential to tackle vaccine equity issues, which are tied to national and regional contexts, but also offers countries an opportunity for longer-term coordination on other priorities.”

::::::

RTS,S Vaccine Procurement

**Millions more children to benefit from malaria vaccine as UNICEF secures supply**

*With malaria one of the biggest killers of children under 5, the world’s first vaccine against a parasite is a major breakthrough for child health*

*Press release*

NEW YORK/COPENHAGEN 16 August 2022 — UNICEF has awarded a contract for the first ever supply of a malaria vaccine to GSK with a value of up to USD 170 million[1]. The landmark award will lead to **18 million doses of RTS,S/AS01 (RTS,S) being available over the next three years**, potentially saving thousands of lives every year.

In 2020, nearly half a million children died from malaria in Africa alone, a rate of one child death per minute.

“This vaccine rollout gives a clear message to malaria vaccine developers to continue their work because malaria vaccines are needed and wanted,” said Etleva Kadilli, Director of UNICEF’s Supply Division. “We hope this is just the beginning. Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market. This is a giant step forward in our collective efforts to save children's lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.”
According to WHO data, more than 30 countries have areas with moderate to high malaria transmission, where the vaccine could provide added protection against malaria to over 25 million children each year once supply scales up.

The RTS,S malaria vaccine is the result of 35 years of research and development and is the first-ever vaccine against a parasitic disease. The vaccine acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa...

"We recently opened the first application window for Gavi support in rolling out the malaria vaccine," said Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance. “Thanks to UNICEF’s procurement work, we now have more certainty on supply and can move a step further towards getting this life-saving vaccine to the people who need it the most. As manufacturing ramps up over time, we hope that increasing volumes will also lead to more sustainable, lower prices.”...

This award is the culmination of 18 months of intensive preparation and consultation with industry and partners. As the largest buyer of vaccines in the world, UNICEF accelerated action to conclude procurement negotiations, to ensure there are no delays in securing available supplies of the malaria vaccine to help protect vulnerable children...

AIDS, Children, 2030

New global alliance launched to end AIDS in children by 2030

Press release

MONTREAL/GENEVA/NEW YORK, 1 August 2022 – Globally, only half (52%) of children living with HIV are on life-saving treatment, far behind adults where three quarters (76%) are receiving antiretrovirals, according to the data that has just been released in the UNAIDS Global AIDS Update 2022. Concerned by the stalling of progress for children, and the widening gap between children and adults, UNAIDS, UNICEF, WHO and partners have brought together a global alliance to ensure that no child living with HIV is denied treatment by the end of the decade and to prevent new infant HIV infections.

The new Global Alliance for Ending AIDS in Children by 2030 was announced by leading figures at the International AIDS Conference taking place in Montreal, Canada.

In addition to the United Nations agencies, the alliance includes civil society movements, including the Global Network of People living with HIV, national governments in the most affected countries, and international partners, including PEPFAR and the Global Fund. Twelve countries have joined the alliance in the first phase: Angola, Cameroon, Côte d’Ivoire, The Democratic Republic of the Congo (DRC), Kenya, Mozambique, Nigeria, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe.

Consultations by the alliance have identified four pillars for collective action:
1. Closing the treatment gap for pregnant and breastfeeding adolescent girls and women living with HIV and optimizing continuity of treatment;
2. Preventing and detecting new HIV infections among pregnant and breastfeeding adolescent girls and women;
3. Accessible testing, optimized treatment, and comprehensive care for infants, children, and adolescents exposed to and living with HIV;
4. Addressing rights, gender equality, and the social and structural barriers that hinder access to services.

...The alliance will run for the next eight years until 2030, aiming to fix one of the most glaring disparities in the AIDS response. Alliance members are united in the assessment that the challenge is surmountable through partnership.

“The wide gap in treatment coverage between children and adults is an outrage,” said UNAIDS Executive Director Winnie Byanyima. “Through this alliance, we will channel that outrage into action. By bringing together new improved medicines, new political commitment, and the determined activism of communities, we can be the generation who end AIDS in children. We can win this – but we can only win together.”

"Despite progress to reduce vertical transmission, increase testing and treatment, and expand access to information, children around the world are still far less likely than adults to have access to HIV prevention, care, and treatment services," said UNICEF Executive Director Catherine Russell. "The launch of the Global Alliance to End AIDS in Children is an important step forward – and UNICEF is committed to working alongside all of our partners to achieve an AIDS-free future."

“No child should be born with or grow up with HIV, and no child with HIV should go without treatment,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “The fact that only half of children with HIV receive antiretrovirals is a scandal, and a stain on our collective conscience. The Global Alliance to End AIDS in Children is an opportunity to renew our commitment to children and their families to unite, to speak and to act with purpose and in solidarity with all mothers, children and adolescents.”...

---

**Featured Journal Content**

**Universal healthcare coverage and health service delivery before and during the COVID-19 pandemic: A difference-in-difference study of childhood immunization coverage from 195 countries**
Sooyoung Kim, Tyler Y. Headley, Yesim Tozan
Research Article | PLOS Medicine published 16 Aug 2022
https://doi.org/10.1371/journal.pmed.1004060

**Abstract**
Background
Several studies have indicated that universal health coverage (UHC) improves health service utilization and outcomes in countries. These studies, however, have primarily assessed UHC’s peacetime impact, limiting our understanding of UHC’s potential protective effects during public health crises such as the Coronavirus Disease 2019 (COVID-19) pandemic. We empirically explored whether countries’ progress toward UHC is associated with differential COVID-19 impacts on childhood immunization coverage.
Methods and findings
Using a quasi-experimental difference-in-difference (DiD) methodology, we quantified the relationship between UHC and childhood immunization coverage before and during the COVID-19 pandemic. The analysis considered 195 World Health Organization (WHO) member states and their ability to provision 12 out of 14 childhood vaccines between 2010 and 2020 as an outcome. We used the 2019 UHC Service Coverage Index (UHC SCI) to divide countries into a “high UHC index” group (UHC SCI ≥80) and the rest. All analyses included potential confounders including the calendar year, countries’ income group per the World Bank classification, countries’ geographical region as defined by WHO, and countries’ preparedness for an epidemic/pandemic as represented by the Global Health Security Index 2019. For robustness, we replicated the analysis using a lower cutoff value of 50 for the UHC index. A total of 20,230 country-year observations were included in the study. The DiD estimators indicated that countries with a high UHC index (UHC SCI ≥80, n = 35) had a 2.70% smaller reduction in childhood immunization coverage during the pandemic year of 2020 as compared to the countries with UHC index less than 80 (DiD coefficient 2.70; 95% CI: 0.75, 4.65; p-value = 0.007). This relationship, however, became statistically nonsignificant at the lower cutoff value of UHC SCI <50 (n = 60). The study’s primary limitation was scarce data availability, which restricted our ability to account for confounders and to test our hypothesis for other relevant outcomes.

Conclusions
We observed that countries with greater progress toward UHC were associated with significantly smaller declines in childhood immunization coverage during the pandemic. This identified association may potentially provide support for the importance of UHC in building health system resilience. Our findings strongly suggest that policymakers should continue to advocate for achieving UHC in coming years.

Author summary
Why was this study done?
- Studies to date have assessed the impact of public health crises on health systems almost exclusively during peacetime and/or under the framework of global health security (GHS).
- According to our literature review, we identified 15 articles that discussed the role of universal health coverage (UHC) on countries’ health system performance in times of public health crises, none of which provided quantitative evidence to substantiate UHC’s potential role in building health system resilience against external shocks like a pandemic.
- To our knowledge, our study is the first attempt to illustrate and quantify the association between countries’ progress in UHC and countries’ ability to protect essential health system delivery during the Coronavirus Disease 2019 (COVID-19) pandemic.

What did the researchers do and find?
- We used a quasi-experimental difference-in-difference (DiD) study design and leveraged the COVID-19 pandemic as a natural experiment to quantify the effect of UHC on childhood immunization coverage before and during the pandemic.
- DiD estimators indicated that countries with a high UHC index (UHC SCI ≥80) were associated a 2.70% smaller decline in childhood immunization coverage during the pandemic year of 2020 as compared to the countries with UHC index less than 80 after adjusting for potential confounders.

What do these findings mean?
- When combined with the extant empirical evidence, our findings strongly suggest that policymakers should continue to advocate for policies aimed at achieving UHC in coming years.
- This study also sets the stage for future research in understanding the synergistic impact of investments in GHS and UHC strategies on countries’ health system resilience.

---

PHEIC

Monkeypox

WHO Director-General’s opening remarks at the COVID-19 media briefing – 17 August 2022

17 August 2022  Speech

Good morning, good afternoon, and good evening.

First, an update on the global monkeypox outbreak. More than 35,000 cases of monkeypox have now been reported to WHO, from 92 countries and territories, with 12 deaths. Almost 7,500 cases were reported last week, a 20% increase over the previous week, which was also 20% more than the week before.

Almost all cases are being reported from Europe and the Americas, and almost all cases continue to be reported among men who have sex with men, underscoring the importance for all countries to design and deliver services and information tailored to these communities that protect health, human rights and dignity.

The primary focus for all countries must be to ensure they are ready for monkeypox, and to stop transmission using effective public health tools, including enhanced disease surveillance, careful contact tracing, tailored risk communication and community engagement, and risk reduction measures.

Vaccines may also play an important part in controlling the outbreak, and in many countries there is high demand for vaccines from the affected communities. However, for the moment, supplies of vaccines, and data about their effectiveness, are limited, although we are starting to receive data from some countries.

WHO has been in close contact with the manufacturers of vaccines, and with countries and organizations who are willing to share doses.

We remain concerned that the inequitable access to vaccines we saw during the COVID-19 pandemic will be repeated, and that the poorest will continue to be left behind.

As we announced last week, a meeting of experts convened by WHO has agreed to rename the two known clades of monkeypox virus using Roman numerals. The clade formerly known as the Congo Basin or Central African clade will now be referred to as clade I, while the West African clade will be called clade II. Work on renaming the disease and the virus is ongoing...

---

Countries approve resolution to support access to monkeypox vaccine in the Americas

As cases reach 10,000 in the Region, Member States hold Special Session of the PAHO Directing Council to discuss best use of limited global vaccine supplies.

Washington D.C. 5 August 2022 (PAHO) – As monkeypox cases continue to rise in several countries of the Americas, Member States of the Pan American Health Organization (PAHO) today held a Special Session of the Directing Council to consider a Resolution to address the outbreak, including supporting equitable access to vaccines for at-risk populations in the region.
On 23 July 2022, the Director of the World Health Organization (WHO) declared the outbreak, which began in mid-May and has affected 89 countries across all six WHO regions, a Public Health Emergency of International Concern (PHEIC). Over 10,000 monkeypox infections have been reported by 24 countries of the Americas since the start of the outbreak. This accounts for 38% of global cases.

“The PHEIC declaration came with detailed recommendations for both countries and territories who haven’t detected any cases as well as for those who already have imported cases or transmission in their communities,” said PAHO Director, Carissa Etienne. “We believe that when the recommended measures are appropriately implemented, we can stop transmission of the monkeypox virus.”

These recommendations, which PAHO is working with Member States to implement, include communication and engagement with affected communities, early detection and surveillance, treatment and isolation of patients, and contact tracing. However, “post- or pre-exposure vaccination might need to complement the other measures,” the Director added...

In light of this, the Resolution adopted requests PAHO’s Director to facilitate a coordinated response and take steps to support Member States in obtaining access to this vaccine through the PAHO Revolving Fund. It also requests that countries of the Region of the Americas continue to recognize PAHO and its Revolving Fund as the strategic regional technical mechanism most suitable for providing equitable access to this vaccine and others.

The recommendations of PAHO’s Technical Advisory Group on Vaccine Preventable Diseases, as well as those of the Emergency Committee of the International Health Regulations, convened by the World Health Organization (WHO), stipulate that countries should prioritize vaccines for specific groups, such as close contacts of a confirmed monkeypox case, in order to maximize impact considering the limited vaccine supply.

---

PHEIC
Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 19 Aug 2022
Confirmed cases :: 591 683 619
Confirmed deaths :: 6 443 306
Vaccine doses administered: 12 409 086 286

---

Weekly epidemiological update on COVID-19 - 17 August 2022
Overview
Globally, the number of new weekly cases decreased by 24% during the week of 8 to 14 August 2022, as compared to the previous week, with over 5.4 million new cases reported. The number of new weekly deaths decreased by 6%, as compared to the previous week, with over 15 000 fatalities reported.

As of 14 August 2022, 587 million confirmed cases and 6.4 million deaths have been reported globally...

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 14 August 2022**

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 07 July 2022
[New additions; Full scale view available at title link above]

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 21 Aug 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]
Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID-19 Vaccine Roll-out

**COVID-19 Data Explorer: Global Humanitarian Operations**

*COVID-19 Vaccine Roll-out*

21 Aug 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 118M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 12.5B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 350M

Other Delivered (Number of Doses): 380M

Total Delivered (Number of Doses): 730M

Total Administered (Number of Doses): 480M
**Global COVID-19 Access Tracker**  
[https://www.covid19globaltracker.org/](https://www.covid19globaltracker.org/)

The ACT-Accelerator and Multilateral Leaders Task Force Global COVID-19 Access Tracker (GCAT) is a dynamic tool to transparently track progress towards the global targets for access to COVID-19 vaccines, treatments, tests and PPE.

**Vaccination**
- 78 countries with vaccination coverage >70%
- 1.61 Bn doses delivered by COVAX to date

**Testing**
- 24 countries testing daily at rate >100/100K pop
- 951 Mn tests delivered via ACTA to date

**Therapeutics**
- All cases cared for in all countries (unavailable)
- US$ 230 Mn treatments & COVID supplies delivered via ACTA to date

**Health Workers**
- All healthcare workers protected (unavailable)
- US$ 565 Mn personal protective equipment (PPE) delivered via ACTA to date

Website accessed 21 Aug 2022: [https://data.covid19taskforce.com/data](https://data.covid19taskforce.com/data)  

The global view below is complemented by country-specific dashboards [here](https://data.covid19taskforce.com/data).
Our World in Data

**Coronavirus (COVID-19) Vaccinations** [Accessed 21 Aug 2022]

:: **67.5%** of the world population has received at least one dose of a COVID-19 vaccine.
:: **12.49 billion doses** have been administered globally, and **5.44 million** are now administered each day.
:: Only **20.7%** of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

**HHS**

*News*

**HHS Facilitates Agreement to Accelerate Delivery of Additional Smallpox and Monkeypox Vaccines Using New U.S. Production Line**
August 18, 2022 | News Release

**Inaugural PandemicX Accelerator Graduates Cohort Creating a Model for Future Public-Private Collaboration**
August 18, 2022 | News Release

**Biden-Harris Administration Makes Hundreds of Thousands More Vaccine Doses Available to Support Monkeypox Response**
August 15, 2022 | News Release

**FDA**

*Press Announcements*

August 9, 2022 - **Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply**
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

*News & Press Releases*

**News: EMA’s Emergency Task Force advises on intradermal use of Imvanex / Jynneos against monkeypox (new)**
Last updated: 19/08/2022

**News: EMA starts review of conditional marketing authorisation application for Skycovion COVID-19 vaccine (new)**
CHMP, Last updated: 18/08/2022

European Centre for Disease Prevention and Control


*Latest Updates [Selected]*

**News**

**Monkeypox situation update, as of 18 August 2022**
Epidemiological update - 19 Aug 2022

**News**

**Weekly COVID-19 country overview**
Epidemiological update - 18 Aug 2022

**News**

**Joint ECDC-WHO/Europe monkeypox surveillance bulletin**
Epidemiological update - 17 Aug 2022

**News**

**Update on the polio situation in the EU/EEA and the world**
News story - 16 Aug 2022

**Publication**

**Monkeypox infection prevention and control guidance for primary and acute care settings**
Guidance - 16 Aug 2022

European Commission


*Latest [Selected]*

**Statement 19 August 2022**

**Statement by Commissioner Kyriakides on the intradermal use of monkeypox vaccine**

Today, the European Medicines Agency (EMA) has advised on intradermal use of monkeypox vaccine.
COVID-19 vaccines: Commission and Moderna adapt delivery schedules for late summer and winter

The European Commission and Moderna have reached an agreement to better address Member States needs for COVID-19 vaccines for the late summer and winter period.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release on 15.06.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/
Government of India – Press Information Bureau

COVID-19 Vaccination Update - Day 583
:: India’s cumulative vaccination coverage crosses 209.98 Crore
:: More than 30 lakh Vaccine doses administered today till 7 pm
Posted On: 21 AUG 2022 8:11PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

-----

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations, leading us to include these reports/observations from the general media below. See China CDC below for additional announcements]

China Covid Cases Jump By 2,200 on Tourist-Spot Flare Ups
:: Country seeking to keep infections under tight control
"" Wider lockdowns pose increasing risks to economic activity
Bloomberg News
August 20, 2022 at 11:04 PM EDT  Updated on August 21, 2022 at 3:16 AM EDT
China reported 2,181 new Covid-19 cases, as conditions worsen in the country’s biggest outbreak since the lockdown of Shanghai earlier this year.
About 553 people were confirmed to be infected and there were another 1,628 asymptomatic cases as of Saturday, according to a statement released by the National Health Commission. In a separate statement, the NHC said the country has administered 3.43 billion doses of Covid vaccines as of Aug. 20...

-----

GPEI - Polio
Polio this week as of 17 Aug 2022
:: Wild poliovirus transmission in Afghanistan is currently at its lowest level in history. Fifty-six children were paralysed by wild polio in 2020. In 2021, the number fell to four. This year to date, only one child has been paralysed, giving the country an extraordinary opportunity to end polio. Read more...

Summary of new polioviruses this week:
– Benin: two cVDPV2 positive environmental samples
– DR Congo: one cVDPV2 positive environmental sample
– Ghana: four cVDPV2 positive environmental samples
– Niger: two cVDPV2 cases and one positive environmental sample
– Nigeria: three cVDPV2 cases and five positive environmental samples
– Yemen: two cVDPV2 cases

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: Flash Update #4 - Flash Flooding in Central, Eastern and South-Eastern Regions (17 August 2022)

Northern Ethiopia
No new digest content identified.

Somalia
No new digest content identified.

Ukraine
Ukraine: Situation Report - Last updated: 17 Aug 2022

WHO & Regional Offices [to 21 Aug 2022]
https://www.who.int/news
Selected News/Announcements/Statement
19 August 2022
News release
WHO makes new recommendations for Ebola treatments, calls for improved access

17 August 2022
Departmental news
Joint Statement: Call for increased political commitment and accountability in preparation for the 2023 United Nations High-Level meeting on Tuberculosis

16 August 2022
WHO releases updated guidance on national strategic planning for tuberculosis

12 August 2022

News release

Monkeypox: experts give virus variants new names

11 August 2022

Statement

Interim statement on COVID-19 vaccination for children

2 August 2022

News release

WHO launches appeal to respond to urgent health needs in the greater Horn of Africa

WHO Director General Speeches [selected]

https://www.who.int/director-general/speeches

Selected

17 August 2022  Speech

WHO Director-General's opening remarks at the COVID-19 media briefing – 17 August 2022

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: Seventy-second session of the WHO Regional Committee for Africa

The Seventy-second session of the WHO Regional Committee for Africa will be held in hybrid format in Lomé, Togo, from 22 to 26 August 2022, under Special procedures for the conduct of the hybrid session of the Regional Committee for Africa.

:: 20 August 2022

The Democratic Republic of the Congo investigates suspected Ebola case in North Kivu

:: 09 August 2022

In Mozambique, household screening keeps families malaria-free

WHO Region of the Americas PAHO

:: 17 Aug 2022

PAHO seeks to strengthen preparedness and response to future respiratory virus pandemics in Latin America and the Caribbean

During a regional workshop in Argentina, the Director of PAHO called for countries to increase investment in epidemic and pandemic preparedness, because the question is not “if there will be a new pandemic, but when”. Buenos Aires, August 17, 2022 (PAHO)- With the aim of supporting countries in Latin America and the Caribbean to develop or...

:: 5 Aug 2022

Countries approve resolution to support access to monkeypox vaccine in the Americas
As cases reach 10,000 in the Region, Member States hold Special Session of the PAHO Directing Council to discuss best use of limited global vaccine supplies.

**WHO South-East Asia Region SEARO**

No new digest content identified.

**WHO European Region EURO**

:: 16 August 2022  News release
**Despite ongoing war and lack of access to care, many refugees return to Ukraine**

:: 10 August 2022  News release
**Polish and Ukrainian medical staff united in providing health support to Ukraine’s refugees**

**WHO Western Pacific Region**

No new digest content identified.

:::

**Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

12 August 2022 | **Leptospirosis - United Republic of Tanzania**

3 August 2022 | **Dengue in Rohingya refugee/Forcibly Displaced Myanmar Nationals (FDMN) camps in Cox’s Bazar - Bangladesh**

:::

**WHO Events**

https://www.who.int/news-room/events/1

[Selected]

**SAVE THE DATE - Scientific strategies from recent outbreaks to help us prepare for Pathogen X**

29 – 30 August 2022

:::

**New WHO Publications**

https://www.who.int/publications/i

**Selected Titles**

19 August 2022

**Therapeutics for Ebola virus disease**

18 August 2022

**Technical consultation on the malaria rebound phenomenon**

18 August 2022
Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19

18 August 2022
Interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19

18 August 2022
Annexes to the interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19

18 August 2022
Background document on the Valneva VLA2001 vaccine against COVID-19

18 August 2022
Good practice statement on the use of second booster doses for COVID-19 vaccines

18 August 2022
Annexes to the recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19

18 August 2022
Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use...

18 August 2022
Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19

17 August 2022
Eighteenth meeting of the United Nations Inter-Agency Task Force on the Prevention and Control of Non-communicable...

15 August 2022
Guidance for national strategic planning for tuberculosis

11 August 2022
Emergency in Ukraine: external situation report #19, published 11 August 2022: reporting period: 28 July–10...

5 August 2022
Implications of the COVID-19 pandemic for patient safety: a rapid review

5 August 2022
Administration of Nirmatrelvir-ritonavir for COVID-19

5 August 2022
Remdesivir for COVID-19

5 August 2022
Administration of Remdesivir for COVID-19
5 August 2022

Safety and monitoring in patients receiving remdesivir for COVID-19
5 August 2022

Safety and monitoring for patients receiving Molnupiravir for COVID-19
5 August 2022

Molnupiravir for COVID-19
5 August 2022

Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19
5 August 2022

Nirmatrelvir-ritonavir for COVID-19
5 August 2022

Administration of Molnupiravir for COVID-19
4 August 2022

Global guidance on criteria and processes for validation: elimination of mother-to-child transmission...
2 August 2022

Malaria surveillance assessment toolkit
2 August 2022

Preparation and administration of REGN-EB3 for Ebola virus disease (EVD)
2 August 2022

Neutralizing monoclonal antibody cocktail REGN-EB3 for Ebola virus disease (EVD)
2 August 2022

Preparation and administration of mAb114 for Ebola virus disease (EVD)
2 August 2022

Neutralizing monoclonal antibody mAb114 for Ebola virus disease (EVD)

CDC/ACIP [U.S.] [to 21 Aug 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
CDC streamlines COVID-19 guidance to help the public better protect themselves and understand their risk

Today, CDC is streamlining its COVID-19 guidance to help people better understand their risk, how to protect themselves and others, what actions to take if exposed to COVID-19, and what actions to take if they are sick or test positive for the virus...


Weekly / August 19, 2022 / 71(33);1057-1064

On August 11, 2022, this report was posted online as an MMWR Early Release.

Greta M. Massetti, PhD1; Brendan R. Jackson, MD1; John T. Brooks, MD1; Cria G. Perrine, PhD1; Erica Reott, MPH1; Aron J. Hall, DVM1; Debra Lubar, PhD1; Ian T. Williams, PhD1; Matthew D. Ritchey, DPT1; Pragna Patel, MD1; Leandris C. Liburd, PhD1; Barbara E. Mahon, MD1 (View author affiliations)

Summary
What is already known about this topic?
High levels of immunity and availability of effective COVID-19 prevention and management tools have reduced the risk for medically significant illness and death.

What is added by this report?
To prevent medically significant COVID-19 illness and death, persons must understand their risk, take steps to protect themselves and others with vaccines, therapeutics, and nonpharmaceutical interventions when needed, receive testing and wear masks when exposed, receive testing if symptomatic, and isolate for ≥5 days if infected.

What are the implications for public health practice?
Medically significant illness, death, and health care system strain can be reduced through vaccination and therapeutics to prevent severe illness, complemented by use of multiple prevention methods to reduce exposure risk and an emphasis on protecting persons at high risk for severe illness.

::::::

ACIP Meetings
Next ACIP Meeting
October 19-20

::::::

MMWR Weekly: Current Volume (71)
August 19, 2022 / No. 33
PDF of this issue
- Progress Toward Measles Elimination — South-East Asia Region, 2003–2020
- COVID-19 Outbreaks and Mortality Among Public Transportation Workers — California, January 2020–May 2022
- Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater — New York, June–August 2022
On Aug 20, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 602 new cases of confirmed infections.

The Chinese mainland on Wednesday reported 614 locally-transmitted confirmed COVID-19 cases, of which 496 were in Hainan Province, the National Health Commission said Thursday.

Azvudine obtained emergency use authorization from the National Medical Products Administration, China's top drug regulator, on July 25, and was included in the latest COVID-19 diagnosis and treatment guideline on Aug 9.
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group  [to 21 Aug 2022]
https://alleninstitute.org/news-press/
News
DNA’s molecular wrinkles: Why you might be older or younger than you think
August 3, 2022
‘Epigenetic clocks’ vary with disease and even by organ, but scientists are still trying to understand why...

BMGF - Gates Foundation  [to 21 Aug 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Press release
Aug 18, 2022
Bill & Melinda Gates Foundation Appoints Two New Members to Board of Trustees
Helene Gayle and Ashish Dhawan will join the foundation’s governance body, helping to strengthen its mission to fight poverty, disease, and inequity globally

Bill & Melinda Gates Medical Research Institute  [to 21 Aug 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
News: Articles and Publications
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022  Press Release
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) — among Janssen Pharmaceutica NV, Otsuka, TB Alliance and the Bill & Melinda Gates Medical Research Institute — supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development.

CARB-X  [to 21 Aug 2022]
https://carb-x.org/
News
07.08.2022
GARDP and CARB-X welcome renewed commitment by G7 leaders to address antimicrobial resistance
The Global Antibiotic Research and Development Partnership (GARDP) and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) jointly welcome the recent G7 Leaders’
Communiqué, which acknowledges the rapid rise in antimicrobial resistance (AMR) globally and renews the commitment by G7 governments to address the most dangerous drug-resistant infections.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 21 Aug 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – Augusts 2022 is now posted here
:: Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations  [to 21 Aug 2022]
http://cepi.net/
Latest News
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.]  [to 21 Aug 2022]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center  [to 21 Aug 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP  [to 21 Aug 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center  [to 21 Aug 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative  [to 21 Aug 2022]
http://www.euvaccine.eu/
Evidence Aid  [to 21 Aug 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/

Selected Resources

Telehealth for the education of rural and remote healthcare workers
Added August 19, 2022

Anxiety in medical students at the start of the COVID-19 pandemic (search done in August 2020)
Added August 16, 2022

Incidence of infectious diseases after earthquakes
Added August 9, 2022

Fondation Merieux  [to 21 Aug 2022]
http://www.fondation-merieux.org/

News, Events
No new digest content identified

Gavi [to 21 Aug 2022]
https://www.gavi.org/
News Releases
5 August 2022
Republic of the Congo to vaccinate more than 4 million people against yellow fever

GHIT Fund  [to 21 Aug 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified

Global Fund  [to 21 Aug 2022]
News & Stories
08 August 2022
Catalytic Investment to Improve Community Health Care for Millions Across Africa
The Global Fund collaborates with the Johnson & Johnson Foundation and the Skoll Foundation to Launch the Africa Frontline First Catalytic Fund
- The Global Fund to Fight AIDS, TB and Malaria intends to further match this commitment by at least with 1:1.
- Designed in partnership with the Africa Frontline First Initiative, the Africa Frontline First Catalytic Fund (AFF-CF) will accelerate scale up of community health services in up to 10 African countries.
- The Catalytic Fund seeks to mobilize at least $100 million to improve community health systems that are providing essential medical care for up to 130 million people.
- Investing in frontline community health workers can generate a return of up to 10:1 when considering the improved economic, health, and social outcomes of community health workers.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 21 Aug 2022]
https://www.glopid-r.org/news/
News
Publication in BMJ Global Health highlights a lack of clinical management guidelines for monkeypox globally
August 18, 2022

Hilleman Laboratories [to 21 Aug 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified

HHMI - Howard Hughes Medical Institute [to 21 Aug 2022]
https://www.hhmi.org/news
Press Room
Research  Aug 18 2022
The Unbreakable Attraction of Mosquitoes to Humans
The blood-dining insect’s neural circuitry for sniffing out its chosen prey is far more complicated and sophisticated than previously thought.

Human Vaccines Project [to 21 Aug 2022]
http://www.humanvaccinesproject.org/
News
What’s New  [Selected]
No new digest content identified.

IAVI [to 21 Aug 2022]
https://www.iavi.org/
Latest News
FEATURES
August 17, 2022
IAVI contributes to WHO proposed framework for evaluating the effectiveness of new COVID-19 vaccines
Global health experts urge developers to plan for vaccine equity in new commentary. New vaccines to combat the evolving SARS-CoV-2 virus should be introduced with vaccine equity in mind, say global health experts in a new commentary published in the journal Vaccine...

ICRC [to 21 Aug 2022]
What’s New [Selected]
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
A Regulatory Pharmaceutical Quality Knowledge Management System (PQ KMS) to Enhance the Availability of Quality Medicines
ICMRA-ICH-PIC/S-IPRP Joint Reflection Paper
Version Dated: 21 July 2022
...This joint Reflection Paper (RP) outlines the coordinated multi-stakeholder approach to harmonization work required to support the development of a regulatory PQ KMS. The harmonization work proposed will contribute to efficiency gains envisioned by the International Coalition of Medicines Regulatory Authorities (ICMRA)6, by supporting greater regulatory reliance*7, agility, and the appropriate, timely and effective sharing of information concerning the state of manufacturers’ pharmaceutical quality and risk management capabilities between global regulatory agencies.

Specifically, the envisaged PQ KMS aims at strengthening international collaboration to support global development, manufacture, and supply of pharmaceutical and biological /biotechnological medicinal products. The PQ KMS will enable further collaboration and reliance in the field of inspections and more convergence among regulators regarding regulatory evaluation of pharmaceutical quality information. Together, this will facilitate manufacturing agility, addition of new manufacturing sites, and strengthen the resilience of global supply chains. A key enabler for delivering the full benefits of a PQ KMS is an enhanced product and process knowledge coupled by a mature on-site PQS...

IFFIm
http://www.iffim.org/
Press Releases/Announcements
IFFIm returns to UK market with £250 million bond supporting Gavi immunisation programmes
19 Jul 2022
IFFIm today priced a £250 million 3-year, fixed-rate bond that will provide immediately available funding for Gavi, the Vaccine Alliance.

IFRC [to 21 Aug 2022]
Press Releases [Selected]
No new digest content identified.
**Institut Pasteur** [to 21 Aug 2022]  
Press Documents  
No new digest content identified.

**IOM / International Organization for Migration** [to 21 Aug 2022]  
News  
No new digest content identified.

**ISC / International Science Council** [to 21 Aug 2022]  
https://council.science/current/  
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.  
News  
No new digest content identified.

**International Union of Immunological Societies (IUIS)**  
https://iuis.org/  
News/Events [Selected]  
No new digest content identified.

**IVAC** [to 21 Aug 2022]  
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html  
Updates; Events  
No new digest content identified.

**IVI** [to 21 Aug 2022]  
http://www.ivi.int/  
IVI News & Announcements  
No new digest content identified.

**Johns Hopkins Center for Health Security** [to 21 Aug 2022]  
https://www.centerforhealthsecurity.org/news/center-news/  
Center News  
New peer-reviewed study documents operational challenges and lessons learned by US public health laboratories during the COVID-19 response  
August 2, 2022 – A new study—conducted by scientists from the Johns Hopkins Center for Health Security and colleagues and published in The Journal of Public Health Management & Practice—
documents challenges faced and lessons learned by local and state public health laboratories (PHLs) during the COVID-19 pandemic response.

In the early days of the pandemic, PHLs across the United States were strained in multiple ways, especially related to developing and deploying COVID-19 tests. The study collects and analyzes information about state and local PHLs’ early COVID-19 experiences to support the development of best practices for current and future health emergencies.

"Identifying Operational Challenges and Solutions During the COVID-19 Response Among US Public Health Laboratories" was conducted by researchers at the Center for Health Security, the Association of Public Health Laboratories, and the Brown University School of Public Health.

In 2021, the researchers interviewed 68 leaders and staff representing 28 local and state PHLs across 27 states. Key challenges identified include:

- A lack of a clear mandate, as PHLs shifted from their traditional surveillance-based testing role to large-scale clinical diagnostic testing;
- Confusing or insufficient operational guidance from federal agencies, including the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA);
- Political interference at the state or local levels; and
- Antiquated information systems limiting testing capacity.

MSF/Médecins Sans Frontières [to 21 Aug 2022]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

National Academy of Medicine - USA [to 21 Aug 2022]
https://nam.edu/programs/
News [Selected]
Statement from the Presidents of the National Academies on Landmark Legislation
August 17, 2022
In a statement released today, the presidents of the National Academies noted the passage of historic legislation for the future of science, engineering, and medicine in the United States. They stated that the work of the National Academies has been and will continue to be centered around the goals laid out in this legislation and [...]

NAM Special Publication on Lessons from COVID-19 Identifies Compelling Needs for Health System Transformation
August 10, 2022
To date, in mid-2022, the United States has lost more than a million people to the COVID-19 pandemic. The American people have been real-time witnesses to scores of heroic responses to the disease, death, inequity, and economic strife unleashed by the virus, but have also experienced the consequences of poor pandemic preparedness and the consequences [...] [See Milestones above for detail]

National Academy of Sciences - USA [to 21 Aug 2022]
News
No new digest content identified.

**National Vaccine Program Office** - U.S. HHS [to 21 Aug 2022]  
https://www.hhs.gov/vaccines/about/index.html  
Upcoming Meetings/Latest Updates  
No new digest content identified.

**NIH** [to 21 Aug 2022]  
http://www.nih.gov/  
News Releases  
**Monoclonal antibody prevents malaria in U.S. adults, NIH trial shows**  
August 4, 2022 — Larger trials enrolling infants and children are underway in Mali and Kenya.

**PATH** [to 21 Aug 2022]  
https://www.path.org/media-center/  
Press Releases  
No new digest content identified.

**Rockefeller Foundation** [to 21 Aug 2022]  
https://www.rockefellerfoundation.org/  
Selected Reports/Press Releases  
Aug 11 2022  
Press Releases  
**The Rockefeller Foundation Funds Initiative to Create 100% Renewable-Powered Climate Neutral District in Glasgow**  
The Foundation was one of the first funders in collaboration with University of Strathclyde and Dalberg Catalyst which will serve as a climate-neutral transition model for cities around the world  
Aug 02 2022  
Press Releases  
**The Rockefeller Foundation Launches the Vaccination Action Network to Strengthen Health Systems and Scale Up Covid-19 Vaccinations in Sub-Saharan Africa**  
Amref Health Africa selected as implementing partner to provide technical assistance for the new peer-to-peer learning network Nairobi  
[See Milestones above for detail]

**Sabin Vaccine Institute** [to 21 Aug 2022]  
https://www.sabin.org/press/  
Latest News & Press Releases  
No new digest content identified.

**UNAIDS** [to 21 Aug 2022]
Selected Press Releases/Reports/Statements
18 August 2022
Second episode of UNAIDS podcast series ‘Against the Odds’ released

16 August 2022
A model for serving key populations from Haiti

12 August 2022
International Youth Day 2022: creating a world for all ages

10 August 2022
Pandemics are not fate: Concrete actions to tackle inequalities can overcome AIDS, Monkeypox and COVID-19

3 August 2022
Empowering young people at youth festivals in Indonesia

UNHCR Office of the United Nations High Commissioner for Refugees [to 21 Aug 2022]
Selected News Releases, Announcements
UNHCR applauds Liberia for removing gender discrimination from its nationality law
11 Aug 2022

UNICEF [to 21 Aug 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
16 August 2022
Millions more children to benefit from malaria vaccine as UNICEF secures supply
NEW YORK/COPENHAGEN 16 August 2022 — UNICEF has awarded a contract for the first ever supply of a malaria vaccine to GSK with a value of up to USD 170 million [1]. The landmark award will lead to 18 million doses of RTS,S/AS01 (RTS,S) being available over the next three years, potentially saving thousands of lives every year. In 2020, nearly half...

Press release
05 August 2022
Haiti: Thousands of children at risk of dying from acute malnutrition if adequate therapeutic care is not provided, UNICEF warns
PORT-AU-PRINCE, 5 August 2022 - An upsurge in gang-related violence has shut access to health services across some urban areas in Haiti, leaving one in 20 children living in Cité Soleil - a violence-
ravaged commune in Port-au-Prince - at risk of dying from severe acute malnutrition, UNICEF warned today. According to latest available data from...

Press release
01 August 2022
New global alliance launched to end AIDS in children by 2030

MONTREAL/GENEVA/NEW YORK, 1 August 2022 – Globally, only half (52%) of children living with HIV are on life-saving treatment, far behind adults where three quarters (76%) are receiving antiretrovirals, according to the data that has just been released in the UNAIDS Global AIDS Update 2022. Concerned by the stalling of progress for children, and...

[Unitedaid](https://unitedaid.org/)
Featured News
16 August 2022
Unitedaid announces a US$45 million investment to increase access to lifesaving products that prevent and treat severe bleeding after childbirth

04 August 2022
Unitedaid landscape report identifies new technologies and innovative delivery strategies that hold promise for reducing vertical transmission of HIV, syphilis, hepatitis B, and Chagas

01 August 2022
Partners announce reduced price for patient-friendly tuberculosis preventive treatments

[Vaccine Equity Cooperative](https://vaccineequitycooperative.org/news/)
News
Apr 07, 2022
Media: Powerful testimonial videos address vaccine hesitancy among new and expectant mothers

[Vaccination Acceptance & Demand Initiative](https://www.vaccineacceptance.org/)
Announcements, Blog
August 16, 2022
Social and Behavioral Research Grants - Call for Proposals
Submission Period Opens: Tuesday, August 16, 2022
Deadline for Submissions: Monday, October 31, 2022, 11:59pm EST
Contact: VaccineAcceptance@sabin.org ApplicationDOWNLOAD CFPFAQ

Sabin is launching its fourth funding cycle of the Social and Behavioral Research Grants program. Successful applicants will be awarded funding for projects to conduct research and implement solutions
for up to 18 months beginning in March 2023. Sabin intends to make awards of up to US$70,000 per funded project.

**Vaccine Confidence Project** [to 21 Aug 2022]
http://www.vaccineconfidence.org/
*News, Research and Reports*
*News*
*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 21 Aug 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
*News*
*No new digest content identified.*

**Wellcome Trust** [to 21 Aug 2022]
https://wellcome.ac.uk/news
*News. Opinion, Reports*
Cheryl Moore
**Wellcome’s approach to research**
3 August 2022
As we announce our first cohort of Discovery Research grantees under our new award scheme, covering a broad range of topics, disciplines and places, I thought I’d take this opportunity to set out how Wellcome’s strategy builds on what we’ve done before, what has changed, what remain as key priorities, and how we will engage with researchers. 3 August 2022

**The Wistar Institute** [to 21 Aug 2022]
*Press Releases*
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 21 Aug 2022]
https://www.wfpha.org/
*Latest News - Blog*
*No new digest content identified.*

**World Bank** [to 21 Aug 2022]
*Selected News, Announcements*
**World Bank Group mobilizes over $20.7 billion to help Latin America and the Caribbean Region respond to overlapping challenges**
Support since the outset of the pandemic show strong engagement in the region WASHINGTON, August 18, 2022 - As Latin America and the Caribbean (LAC) continues to deal with the negative impact of the...
Date: August 18, 2022 Type: Press Release

**World Bank Group Outlines Global Crisis Response Package to Help Developing Countries Navigate Multiple, Compounding Crises**
WASHINGTON, August 3, 2022 – The World Bank Group (WBG) today announced details of its global crisis response package to help developing countries navigate multiple, compounding crises that are hitting...
Date: August 03, 2022 Type: Press Release

**World Customs Organization – WCO** [to 21 Aug 2022]
http://www.wcoomd.org/
Latest News
No new digest content identified.

**World Organisation for Animal Health (OIE)** [to 21 Aug 2022]
https://www.oie.int/en/
Press Releases, Statements
Published on 12 August 2022
While the monkeypox outbreak continues to spread amongst humans, the World Organisation for Animal Health (WOAH, founded as OIE) explains the precautions to take in order to protect animals from the increase in reverse spillover of the disease back into animals.

**WTO - World Trade Organisation** [to 21 Aug 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
No new digest content identified.

::::

**ARM [Alliance for Regenerative Medicine]** [to 21 Aug 2022]
Selected Press Releases
The Alliance for Regenerative Medicine Announces the Appointment of Timothy D. Hunt as Chief Executive Officer
August 10, 2022  Washington, D.C.
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy sector, today formally announced that its Board of Directors has appointed Timothy D. Hunt as the organization’s next Chief Executive Officer.

**BIO** [to 21 Aug 2022]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 21 Aug 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 21 Aug 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 21 Aug 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO [to 21 Aug 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

PhRMA [to 21 Aug 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

::::::
::::::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases
Aug 15: **Bharat Biotech completes clinical development for phase III trials and booster doses for BBV154 intranasal covid vaccine**

BioCubaFarma – Cuba
*Últimas Noticias* - No new digest announcements identified

**Biological E**
*News*
**CORBEVAX Approved as India’s First Heterologous COVID-19 Booster Shot for 18 Years and Above**
- CORBEVAX is expected to be available as a Booster dose on the CoWIN App in Public and Private Vaccination Centres from August 12, 2022
- Many countries have adopted the Heterologous Booster dose over the homologous booster dose to target better vaccination outcomes, particularly against emerging variants
- CORBEVAX has demonstrated a significantly increased immune response to the Omicron strain

Hyderabad, August 11, 2022:

BioNTech
*Press Releases*
**BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates**
05 Aug 2022

CanSinoBIO
*News* - Website not responding at inquiry

CIGB
*Latest News* - No new digest announcements identified

Cinnagen
*Recent News* - No new digest announcements identified

Clover Biopharmaceuticals - China
*News* - No new digest announcements identified

CureVac  [Bayer Ag – Germany]
*News*
August 18, 2022
**CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate**

Gamaleya National Center
*Latest News and Events* - See Russia below.

GSK
*Press releases for media* - No new digest announcements identified
Merck
News releases
August 16, 2022
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

Moderna
Press Releases
15 August, 2022
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna’s Omicron-Containing Bivalent Booster in the UK

09 August, 2022
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses

Novavax
Press Releases
Aug 19, 2022

Aug 18, 2022
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Aug 17, 2022
Novavax’ COVID-19 Vaccine Recognized in U.S. Government Delegation Visit to Serum Institute of India

Aug 17, 2022
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
Aug 15, 2022
Novavax Files in Taiwan for Expanded Emergency Use Authorization of Nuvaxovid™ COVID-19 Vaccine in Adolescents Aged 12 Through 17

Aug 15, 2022
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

Aug 12, 2022
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17

Aug 10, 2022

Aug 4, 2022
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years

Aug 1, 2022
Statement - Novavax Statement on U.S. Vaccinations with the Novavax COVID-19 Vaccine, Adjuvanted Underway

Pfizer
Recent Press Releases
08.15.2022
Updates and Statements
Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19 COVID-19

08.12.2022
Press Releases
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

08.08.2022
Press Releases
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 Research and Pipeline

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Sinovac

Press Releases

**Sinovac Beijing’s QC Laboratory Accredited By CNAS**

August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Quality Control (QC) laboratory of its subsidiary Sinovac Beijing, has been accredited by the China National Accreditation Service for Conformity Assessment (CNAS), confirming the lab meets ISO 17025 global standards for operational competence and validity.

**SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong**

2022/08/15

SK Biosciences

Press Releases

**SK-Bill & Melinda Gates Foundation met to discuss shared commitments to global health**

2022.08.16

**SK bioscience Announces Adolescent Authorization of Protein Based COVID-19 Vaccine, Nuvaxovid**

SK extends the vaccination age of Nuvaxovid to 12 to 17-year-olds

2022.08.12

**SK bioscience Submits Application for Conditional Marketing Authorization of COVID-19 Vaccine, SKYCovion™ to European Medicines Agency**

SK bioscience will accelerate to apply for emergency use listing (EUL) to the World Health O...

2022.08.01

Valneva

Press Releases

**Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate**

August 18, 2022

**Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense**

August 18, 2022
August 8, 2022

**Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15**

August 1, 2022

**Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine**

**Vector State Research Centre of Viralogy and Biotechnology**

*Home* - [Website not responding [404 error]]

**WestVac Biopharma**

*Media* - [No new digest announcements identified]

**Zhifei Longcom**, China  
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  
[No website identified]

---

**Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

**AJOB Empirical Bioethics**

Volume 13, 2022 Issue 3  
[https://www.tandfonline.com/toc/uabr21/current]

**Article**  
*Ethical Challenges Experienced by Healthcare Workers Delivering Clinical Care during Health Emergencies and Disasters: A Rapid Review of Qualitative Studies and Thematic Synthesis*  
Mariana Dittborn, Constanza Micolich, Daniela Rojas & Sofía P. Salas  
Pages: 179-195  
Published online: 25 Apr 2022

**Article**  
*Advancing a Data Justice Framework for Public Health Surveillance*  
Mara Buchbinder, Eric Juengst, Stuart Rennie, Colleen Blue & David L. Rosen  
Pages: 205-213
Bioethical debates about privacy, big data, and public health surveillance have not sufficiently engaged the perspectives of those being surveilled. The data justice framework suggests that big data applications have the potential to create disproportionate harm for socially marginalized groups. Using examples from our research on HIV surveillance for individuals incarcerated in jails, we analyze ethical issues in deploying big data in public health surveillance.

**AMA Journal of Ethics**
Volume 24, Number 8: E715-816  Aug 2022  
https://journalofethics.ama-assn.org/issue/inequity-and-iatrogenic-harm

**Inequity and Iatrogenic Harm**
Three kinds of health inequity include (1) inequity in access to health care; (2) inequity in the quality of health care services, experiences, and interactions; and (3) inequity in health status. Iatrogenic harms include damage generated by health care services, experiences, and interactions and are not limited to errors. Should neglect by health care organizations and personnel also count as forms of iatrogenic harm to patients and communities? This theme issue considers this question and considers, too, how iatrogenic harm exacerbates inequity and how different kinds of inequity exacerbate iatrogenesis. The health of persons whose embodiment experiences and identities are minoritized along axes of gender, race, class, ethnicity, and comorbidities could very well rely upon what is revealed by deeply interrogating the nature and scope of ethical, clinical, legal, and social relationships between iatrogenic harm and health inequity.

**American Journal of Infection Control**
August 2022 Volume 50 Issue 8  p839-968  
http://www.ajicjournal.org/current

**WHO Special issue: Personal protective equipment research and innovation in the context of the World Health Organization COVID-19 R&D Blueprint program**

**Commentary**
**Personal protective equipment research and innovation in the context of the World Health Organization COVID-19 R&D Blueprint program**
Madison Moon, Leandro Pecchia, Adriana Velazquez Berumen, April Baller  
Published in issue: August 2022  
p839-843

In February 2020, in response to the coronavirus disease 2019 (COVID-19) pandemic, the World Health Organization (WHO) organized a Global Forum on Research and Innovation for COVID-19 (ie, Global Research Forum), which highlighted the importance of fostering research and innovation in the area of infection prevention and control (IPC), including rational and appropriate use of well-designed personal protective equipment (PPE). Despite its utmost importance for global health, PPE had not been prioritized in the research and innovation agendas of funding agencies and research institutions. Thus, at the start of the pandemic, knowledge gaps existed about PPE use by health workers outside the normative use during single encounters as part of infection transmission precautions. This was the case for extended use, to ration availability, and mask use in community settings as a supplementary emergency measure where epidemic containment strategies (testing, isolation, contact tracing, and quarantine) were unable to effectively identify and manage widespread community transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
The goals of the Global Research Forum were to accelerate research for containing the spread of SARS-CoV-2 and help those affected to receive optimal care. This required: identifying and supporting research priorities; creating a global research platform; and strengthening preparedness for prompt information-sharing to bridge gaps in COVID-19 response knowledge and prevent another unforeseen epidemic. This forum was pivotal to encouraging accelerated development of diagnostics, therapeutics and vaccines and ensuring equitable access based on public health needs.

One output of the Global Research Forum was the publication of the coordinated global research roadmap. This roadmap identified nine priority research priorities, one of which was IPC, including health workers’ protection.

This commentary provides an overview of WHO's activities on IPC/PPE in the context of the R&D Blueprint for COVID-19, introduces nine PPE-focused research projects funded through the WHO R&D Blueprint for COVID-19, and reports on the current research priorities on PPE identified in the last WHO Global Research Forum, held in February 2022.

---

**American Journal of Preventive Medicine**
September 2022  Volume 63  Issue 3  p313-468
https://www.ajpmonline.org/current
[New issue; No digest content identified]

**American Journal of Public Health**
September 2022  112(9)
http://ajph.aphapublications.org/toc/ajph/current
NOTES FROM THE FIELD
**A Social Media‒Based Public Health Campaign Encouraging COVID-19 Vaccination Across the United States**
Health Promotion, Public Health Practice
Isabella de Vere Hunt, Tamara Dunn, Megan Mahoney, Michael Chen, Vanessa Nava and Eleni Linos

**Human Papillomavirus Vaccinations During the COVID-19 Pandemic in Middle Schools in the Rio Grande Valley of Texas**
Low-Income Children, Immunization/Vaccines, Child and Adolescent Health, School Health, Adolescent Health
Ana M. Rodriguez, Thuy Quynh N. Do, Maria L. Jibaja-Weiss, Lu Chen, Kathleen M. Schmeler, Jane R. Montealegro and Yong-Fang Kuo

**American Journal of Tropical Medicine and Hygiene**
Volume 106 (2022): Issue 6 (Jun 2022)
https://www.ajtmh.org/view/journals/tpmd/106/6/tpmd.106.issue-6.xml
[Reviewed earlier]

**Annals of Internal Medicine**
August 2022  Volume 175, Issue 8
http://annals.org/aim/issue
Original Research
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 - A Randomized, Placebo-Controlled Trial
FREE
Matthew G. Johnson, MD, Amy Puenpatom, PhD, Pablo Andrés Moncada, MD, ... et al.
Pages:1126–1134

Ideas and Opinions
A Novel International Monkeypox Outbreak
FREE
Amesh Adalja, MD, Tom Inglesby, MD
Pages:1175–1176

Monkeypox: Avoiding the Mistakes of Past Infectious Disease Epidemics
FREE
Demetre Daskalakis, MD, MPH, R. Paul McClung, MD, Leandro Mena, MD, MPH, ... et al.
Pages:1177–1178

Adding New Fuel to the Fire: Monkeypox in the Time of COVID-19—Implications for Health Care Personnel
FREE
Tara N. Palmore, MD, David K. Henderson, MD
Pages:1183–1184

Artificial Intelligence – An International Journal
Volume 309 August 2022
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 21 Aug 2022)
[No new digest content identified]

BMJ Global Health
July 2022 - Volume 7 - 7
https://gh.bmj.com/content/7/7
Editorial
Whole of government and whole of society approaches: call for further research to improve population health and health equity (29 July, 2022)
Flaminia Ortenzi, Robert Marten, Nicole B Valentine, Aku Kwamie, Kumanan Rasanathan

Commentary
Evaluating potential unintended consequences of COVID-19 vaccine mandates and passports (29 July, 2022)
Maxwell J Smith
**Economic sanctions, healthcare and the right to health** (26 July, 2022)
Federico Germani, Julian W. März, Caroline Clarinval, Nikola Biller-Andorno

**A pandemic treaty for equitable global access to medical countermeasures: seven recommendations for sharing intellectual property, know-how and technology** (15 July, 2022)

**Original research**
**When do persuasive messages on vaccine safety steer COVID-19 vaccine acceptance and recommendations? Behavioural insights from a randomised controlled experiment in Malaysia** (29 July, 2022)
Nicholas Yee Liang Hing, Yuan Liang Woon, Yew Kong Lee, Hyung Joon Kim, Nurhyikmah M Lothfi, Elizabeth Wong, Komathi Perialathan, Nor Haryati Ahmad Sanusi, Affendi Isa, Chin Tho Leong, Joan Costa-Font

**Aboriginal peoples’ perspectives about COVID-19 vaccines and motivations to seek vaccination: a qualitative study** (20 July, 2022)
Simon Graham, Megan Blaxland, Reuben Bolt, Mitchell Beadman, Kristy Gardner, Kacey Martin, Michael Doyle, Karen Beetsone, Dean Murphy, Stephen Bell, Christy E Newman, Joanne Bryant

**Equity assessment of childhood immunisation at national and subnational levels in Myanmar: a benefit incidence analysis** (8 July, 2022)
Zin Mar Win, Tom Traill, Zarni Lynn Kyaw, Khaing Thandar Hnin, Phway Thinzar Chit, Thazin La, Ashwini Sunil Deshpande, Osondu Ogbouji, Wenhui Mao

**A systematic review of newborn health interventions in humanitarian settings** (1 July, 2022)
Mariana Rodo, Diane Duclos, Jocelyn DeJong, Chaza Akik, Neha S Singh

**BMC Health Services Research**
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 21 Aug 2022)
**Modelling vaccination capacity at mass vaccination hubs and general practice clinics: a simulation study**
COVID-19 mass vaccination programs place an additional burden on healthcare services. We aim to model the queueing process at vaccination sites to inform service delivery.
Authors: Mark Hanly, Tim Churches, Oisín Fitzgerald, Ian Caterson, Chandini Raina MacIntyre and Louisa Jorm
Citation: BMC Health Services Research 2022 22:1059
Content type: Research Published on: 19 August 2022

“Intention to receive COVID-19 vaccine among healthcare workers: a comparison between two surveys”
Considering the importance of intention to receive COVID-19 vaccine among healthcare workers and its role in maintaining their health and inhibiting the epidemic spread of Covid-19, the present study was done ...

Authors: Alipasha Meysamie, Elham Ghasemi, Shadi Moshksar and Mehrdad Askarian
Citation: BMC Health Services Research 2022 22:982
Content type: Research Published on: 1 August 2022

**BMC Infectious Diseases**
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 21 Aug 2022)
[No new digest content identified]

**BMC Medical Ethics**
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 21 Aug 2022)

*Biobanks in the low- and middle-income countries of the Arab Middle East region: challenges, ethical issues, and governance arrangements—a qualitative study involving biobank managers*

Biobanks have recently been established in several low- and middle-income countries (LMICs) in the Arab region of the Middle East. We aimed to explore the views of biobank managers regarding the challenges, et...

Authors: Ahmed Samir Abdelhafiz, Mamoun Ahram, Maha Emad Ibrahim, Alya Elgamri, Ehsan Gamel, Rania Labib and Henry Silverman
Citation: BMC Medical Ethics 2022 23:83
Content type: Research Published on: 14 August 2022

**BMC Medicine**
http://www.biomedcentral.com/bmcmed/content
(Accessed 21 Aug 2022)
[No new digest content identified]

**BMC Pregnancy and Childbirth**
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 21 Aug 2022)

*Hesitancy about COVID-19 vaccination among pregnant women: a cross-sectional study based on the health belief model*

Pregnant women are at high risk for affliction by coronavirus disease 2019 (COVID-19). Vaccination is a main strategy to prevent and manage the COVID-19 pandemic. However, hesitancy about COVID-19 vaccination ...

Authors: Mojgan Firouzbakht, Hamid Sharif Nia, Fatemeh Kazeminavaei and Pegah Rashidian
Citation: BMC Pregnancy and Childbirth 2022 22:611
Content type: Research Published on: 2 August 2022
**BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles

(Accessed 21 Aug 2022)

**“To do, or not to do?”: determinants of stakeholders’ acceptance on dengue vaccine using PLS-SEM analysis in Malaysia**

Dengue vaccine is a promising alternative for protecting communities from dengue. Nevertheless, public acceptance of the dengue vaccine must be considered before the authorities decide to carry out intensified...

Authors: Ahmad Firdhaus Arham, Latifah Amin, Muhammad Adzran Che Mustapa, Zurina Mahadi, Mashitoh Yaacob, Ahmad Fadhly Arham and Nor Sabrena Norizan

Citation: BMC Public Health 2022 22:1574

Content type: Research Published on: 19 August 2022

**Parental decision and intent towards COVID-19 vaccination in children with asthma: an econometric analysis**

Vaccination will be instrumental in controlling the COVID-19 pandemic, and vaccination of children will be necessary to achieve herd immunity. Given that children with chronic health conditions may be at incre...

Authors: Olivier Drouin, Pierre Fontaine, Yann Arnaud, Claude Montmarquette, Alexandre Prud’homme and Roxane Borgès Da Silva

Citation: BMC Public Health 2022 22:1547

Content type: Research Published on: 13 August 2022

**COVID-19 vaccine adoption and hesitancy among older Veterans**

Older adults are particularly at risk for severe illness or death from COVID-19. Accordingly, the Veterans Health Administration (VA) has prioritized this population group in its COVID-19 vaccination strategy....

Authors: Tamar Wyte-Lake, Cari Levy, Sona Hovsepian, Yvonne Mudoh, Cheryl Schmitz and Aram Dobalian

Citation: BMC Public Health 2022 22:1532

Content type: Research Published on: 11 August 2022

**Which countries need COVID-19 vaccines the most? Development of a prioritisation tool**

The COVID-19 pandemic and associated non-pharmaceutical interventions (NPIs) have affected all countries. With a scarcity of COVID-19 vaccines there has been a need to prioritize populations, but assessing rel...

Authors: Vageesh Jain, Rifat Atun, Paul Hansen and Paula Lorgelly

Citation: BMC Public Health 2022 22:1518

Content type: Research Published on: 10 August 2022

**BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content

(Accessed 21 Aug 2022)

[No new digest content identified]
**Bulletin of the World Health Organization**

**Volume 100(8); 2022 Aug 1**

https://www.ncbi.nlm.nih.gov/pmc/issues/412939/

**Editorials**

**Innovation in diagnostics: addressing gaps in low- and middle-income countries**

Claudia Chamas, Mady Malheiros Barbeitas, Marilena Correa, Koichi Kameda, Ana Claudia Dias de Oliveira, Luiz Villarinho

Bull World Health Organ. 2022 Aug 1; 100(8): 467–467A. Published online 2022 Aug 1.

doi: 10.2471/BLT.22.288313

PMCID: PMC9306385

**Research**

**COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran**


Bull World Health Organ. 2022 Aug 1; 100(8): 474–483. Published online 2022 Jun 22.

doi: 10.2471/BLT.22.288073

PMCID: PMC9306382

**Systematic Reviews**

**Controlled temperature chain for vaccination in low- and middle-income countries: a realist evidence synthesis**

Christopher P Seaman, Anna-Lea Kahn, Debra Kristensen, Robert Steinglass, Dijana Spasenoska, Nick Scott, Christopher Morgan

**Policy & Practice**

**National medicines policy development, Saudi Arabia**
Khalid Almoteiry, Adel Alharf, Bandar Al Hammad, Ibrahim Aljuffali, Nahar Al-Azemi, Taghred Al-Ghaith, Shahad Alhomidi, Ahlam Alshehri, Andreas Seiter, Christopher Herbst, Elizabeth Pisani
Bull World Health Organ. 2022 Aug 1; 100(8): 511–519. Published online 2022 Jun 22.
doi: 10.2471/BLT.22.287936
PMCID: PMC9306383

**Cell**
Aug 18, 2022 Volume 185 Issue 17 p3059-3278
https://www.cell.com/cell/current
[New issue; No digest content identified]

**Child Care, Health and Development**
Volume 48, Issue 5 Pages: 659-879 September 2022
https://onlinelibrary.wiley.com/toc/13652214/current
[New issue; No digest content identified]

**Clinical Pharmacology & Therapeutics**
Volume 112, Issue 2 Pages: 181-412 August 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[New issue; No digest content identified]

**Clinical Therapeutics**
June 2022 Volume 44 Issue 6 p825-926
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

**Clinical Trials**
Volume 19 Issue 4, August 2022
https://journals.sagepub.com/toc/ctja/19/4

*Conference Proceedings*
**Proceedings of the University of Pennsylvania 13th annual conference on statistical issues in clinical trials: Cluster randomized clinical trials—Challenges and opportunities**
Susan S Ellenberg, Jonas H Ellenberg
First Published June 9, 2022; pp. 351–352

*Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters*
Victor DeGruttola, Ravi Goyal, Natasha K Martin, Rui Wang
First Published July 27, 2022; pp. 363–374

*The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks*
Natalie E Dean, Ira M Longini
Reviews

Current recommendations/practices for anonymising data from clinical trials in order to make it available for sharing: A scoping review
Aryelly Rodriguez, Christopher Tuck, Marshall F Dozier, Stephanie C Lewis, Sandra Eldridge, Tracy Jackson, Alastair Murray, Christopher J Weir
First Published June 22, 2022; pp. 452–463

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 21 Aug 2022]
[No new digest content identified]

Contemporary Clinical Trials
Volume 118  July 2022
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/118/suppl/C
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 4 / August 2022
https://www.liebertpub.com/toc/crispr/5/4
[New issue; No digest content identified]

Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
June 2022 - Volume 35 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
EMBO Reports
Volume 23 Issue 8  3 August 2022
https://www.embopress.org/toc/14693178/current
Review 18 July 2022
Molecular adaptations during viral epidemics
Nash D Rochman, Yuri I Wolf, Eugene V Koonin
This review comprehensively describes the molecular adaptation of variola virus, HIV-1 M, SARS, H1N1-SIV, MERS, Ebola, Zika, and SARS-CoV-2 to the human host and identifies the key factors in the evolution of epidemic viruses.
The effect of COVID-19 on public confidence in the World Health Organization: a natural experiment among 40 countries

At a time when a highly contagious pandemic and global political and economic turmoil are intertwined, worldwide cooperation under the leadership of an international organization has become
increasingly important. This study aimed to estimate the effect of COVID-19 on public confidence in the World Health Organization (WHO), which will serve as a reference for other international organizations regarding the maintenance of their credibility in crisis management and ability to play a greater role in global health governance.
Authors: Chao Guo, Xiyuan Hu, Dianqi Yuan, Yuyu Zeng and Peisen Yang
Citation: Globalization and Health 2022 18:77
Content type: Research Published on: 20 August 2022

Health and Human Rights
Volume 24, Issue 1, June 2022
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 3 - July 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 6, June 2022
https://academic.oup.com/heapol/issue/37/6
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 21 Aug 2022]
What funders are doing to assess the impact of their investments in health and biomedical research
As pressures to maximize research funding grow, biomedical research funders are increasingly tasked with demonstrating the long-term and real-world impacts of their funded research investments. Over the past three decades, research impact assessments (RIA) have emerged as an important tool for analysing the impacts of research by incorporating logic models, frameworks and indicators to track measures of knowledge production, capacity-building, development of research products, adoption of research into clinical guidelines and policies, and the realization of health, economic and social benefits. While there are currently several models for RIA within the literature, less attention has been paid to how funders can practically select and implement a RIA model to demonstrate the impacts of their own research portfolios. In this paper, a literature review was performed to understand (1) which research funders have performed RIAs of their research portfolios to date; (2) how funders have designed their assessments, including the models and tools they have used; (3) what challenges to and facilitators of success have funders found when adopting the RIA model to their own portfolio; and (4) who participates in the assessments...
Authors: Rachel Abudu, Kathryn Oliver and Annette Boaz
Citation: Health Research Policy and Systems 2022 20:88
Content type: Review Published on: 9 August 2022
**Human Gene Therapy**
Volume 33, Issue 15-16 / August 2022
https://www.liebertpub.com/toc/hum/33/15-16
[New issue; No digest content identified]

**Humanitarian Practice Network**
https://odihrn.org/
Featured Publications
[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

**Immunity**
Aug 09, 2022 Volume 55 Issue 8 p1329-1514
https://www.cell.com/immunity/current
Articles
**Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3**
Min Huang, et al.
Open Access
The evolution of SARS-CoV-2 variants of concern brings new challenges toward host immunity and protection. Huang et al. tested the neutralization potency of 50 human mAbs against Omicron sub-variants BA.1, BA.1.1, BA.2, and BA.3. Structural analysis of three mAbs provides further insight into the immune evasion capacity of Omicron sub-variants.

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/
[Accessed 21 Aug 2022]
[No new digest content identified]

**Infectious Diseases of Poverty**
http://www.idpjournal.com/content
[Accessed 21 Aug 2022]
[No new digest content identified]

**International Health**
Volume 14, Issue 4, July 2022
Minor Consent Laws for Sexually Transmitted Infection and HIV Services
Kimberly M. Nelson, PhD, MPH; Alexandra Skinner, MPH; Kristen Underhill, DPhil, JD
JAMA. 2022;328(7):674-676. doi:10.1001/jama.2022.10777
This study examines current minor consent laws for sexually transmitted infection/HIV services and related confidentiality protections in all 50 states and the District of Columbia.

Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers
Elena Azzolini, MD, PhD; Riccardo Levi, MSc; Riccardo Sarti, MSc; et al.
free access has active quiz has multimedia has audio
This study examines the risk of long COVID following mRNA vaccination, compared with no vaccination, in health care workers in Italy who had COVID-19 infection.

Viewpoint
The WHO Declaration of Monkeypox as a Global Public Health Emergency
Jennifer B. Nuzzo, DrPH, SM; Luciana L. Borio, MD; Lawrence O. Gostin, JD
free access has active quiz has audio
This Viewpoint examines the ongoing monkeypox outbreak and the recent decision by the director-general of the World Health Organization to declare a Public Health Emergency of International Concern.

August 9, 2022, Vol 328, No. 6, Pages 497-593
[No digest content identified]

August 2, 2022, Vol 328, No. 5, Pages 409-486
Research Letter
Reported Interest in Notification Regarding Use of Health Information and Biospecimens
Kayte Spector-Bagdady, JD, MBE; Grace Trinidad, PhD, MPH, MS; Sharon Kardia, PhD; et al.
This study describes reported interest in notification regarding use of personal health information and biospecimens for research and preference-associated factors among a sample of the US population in 2019.

Review
Diagnosis, Treatment, and Prevention of Malaria in the USA Review
Johanna P. Daily, MD, MS; Aurelia Minuti, MLS; Nazia Khan, MD, MSc, DTMH
has active quiz has audio
This Review discusses the epidemiology, prevention, and treatment of malaria in the US.

JAMA Pediatrics
August 2022, Vol 176, No. 8, Pages 737-830
https://jamanetwork.com/journals/jamapediatrics/currentissue
Research Letter
Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US
Lindsey Wang; Nathan A. Berger, MD; David C. Kaelber, MD, PhD; et al.
free access
This cohort study assesses the incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative
Blake Martin, MD; Peter E. DeWitt, PhD; Seth Russell, MS; et al.
open access has active quiz
This cohort study uses data from the US National COVID Cohort Collaborative to evaluate upper airway infections in children during the surge of the Omicron (B.1.1.529) variant of SARS-CoV-2 in the US.
Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children Before and During the Omicron Wave
Mette Holm, PhD; Laura Espenhain, MSc; Jonathan Glenthøj, MD; et al.
This cohort study investigates the risk of multisystem inflammatory syndrome after SARS-CoV-2 infection in vaccinated and unvaccinated children before and during the Omicron wave in Denmark.

JBI Evidence Synthesis
August 2022 - Volume 20 - Issue 8
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Adolescent Health
August 2022  Volume 71  Issue 2  p141-250
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 74 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 4, August 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-4
[Reviewed earlier]

Journal of Development Economics
Volume 158  September 2022
Research article  Full text access
Cash transfers as a response to COVID-19: Experimental evidence from Kenya
Wyatt Brooks, Kevin Donovan, Terence R. Johnson, Jackline Oluoch-Aridi
Article 102929

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 3, July 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
Journal of Evidence-Based Medicine
Volume 15, Issue 2  Pages: 73-179  June 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[New issue; No digest content identified]

Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current
Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 2, May 2022
https://muse.jhu.edu/issue/47787
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 5, October 2022
Contents
Perceived Vulnerability to Disease, Knowledge and Preventive Behavior Related to COVID-19 in Farsi and Arabic Speaking Refugees
Schahryar Kananian, Samar Al-Sari, Ulrich Stangier
Content type: Original Paper
Open Access
Published: 10 December 2021
Pages: 1245 - 1250

Journal of Immigrant & Refugee Studies
Volume 20, 2022 , Issue 3
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 225, Issue 12, 15 June 2022
https://academic.oup.com/jid/issue/225/12
Journal of International Development
Volume 34, Issue 6  Pages: 1069-1255  August 2022
https://onlinelibrary.wiley.com/toc/10991328/current
[New issue; No digest content identified]

Journal of Medical Ethics
August 2022 - Volume 48 - 8
http://jme.bmj.com/content/current
Current controversy
Priority vaccination for mental illness, developmental or intellectual disability (7 April, 2021)
Free
Nina Shevzov-Zebrun, Arthur L Caplan

Original research
COVID-19 conscience tracing: mapping the moral distances of coronavirus (8 June, 2021)
Free
David Shaw

COVID-19 vaccination and the right to take risks (12 July, 2021)
Pei-hua Huang

Why we should not ‘just use age’ for COVID-19 vaccine prioritisation (9 July, 2021)
Maxwell J Smith

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 3 (2022)
https://institutionalrepository.aah.org/jpcrr/
Original Research
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies
Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, and James L. Weese

Journal of Pediatrics
July 2022  Volume 246  p1-294
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 21 Aug 2022]
Original Research

Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies

Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, and James L. Weese

An analysis of COVID-19 information sources

The COVID-19 pandemic has brought new situations that require the effective delivery of health information across the world and it’s important to offer clear, consistent, and credible information on the pandemic...

Authors: Belachew Umata, Temesgen Mulugeta, Girma Mamo, Sintayehu Alemu, Nimona Berhanu, Gudina Milkessa, Birhanu Mengistu and Tsegaye Melaku

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:49

Content type: Research Published on: 17 August 2022
From October to November, 2021, the pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medications to the Medicines Patent Pool (MPP). In both cases, the drugs were licensed quickly, before they were launched, and the MPP then reached agreements with pharmaceutical firms across the globe (27 firms for Merck's molnupiravir and 36 firms for Pfizer's nirmatrelvir) to provide generic versions of these to roughly 100 low-income and middle-income countries. This Viewpoint examines the importance of these licences for the global production of, and access to, new medicines, during the pandemic and beyond. It would be a welcome development for these arrangements, which can generate sufficient volumes of production to avoid the supply shortages that encumbered the global vaccination response, to be an indication of a future in which new drugs have multiple suppliers in most low-income and middle-income countries. To explore that possibility, the Viewpoint highlights the political conditions that could make originator firms more inclined to license their products quickly to the MPP, and discusses how public policy can build on the opportunity created by these conditions to promote such licensing further.

Many high-income countries have rapidly pivoted from hard decisions about who may receive COVID-19 vaccines, due to shortages, to equally hard decisions about who must receive them. As lasting containment of COVID-19 remains elusive, many nations—from Costa Rica, to Austria, to Turkmenistan—are turning to vaccination mandates of various kinds. Mandates, however, are controversial in many countries. Austria's proposed mandate for adults, for example, provoked mass protests. Some objectors argue mandates represent undue encroachment on individual liberty. Some other objectors maintain that mandates will not be an effective policy for COVID-19 because many individuals will seek to evade them, and mandates might erode support for other public health measures such as mask wearing.

In this Viewpoint we consider the likely effectiveness of policies that require COVID-19 vaccines in improving vaccine uptake and reducing disease in the USA, in view of the evidence from past vaccination mandates and distinctive aspects of COVID-19. Two dimensions of effectiveness in improving uptake are relevant: (1) target-group effectiveness (the extent to which a mandate improves uptake of vaccines in the group covered by the policy) and (2) population effectiveness (the extent to which mandate policies improve vaccination coverage in the US population).
International law reform for One Health notifications
Colin J Carlson, Alexandra L Phelan

Summary
Epidemic risk assessment and response relies on rapid information sharing. Using examples from the past decade, we discuss the limitations of the present system for outbreak notifications, which suffers from ambiguous obligations, fragile incentives, and an overly narrow focus on human outbreaks. We examine existing international legal frameworks, and provide clarity on what a successful One Health approach to proposed international law reforms—including a pandemic treaty and amendments to the International Health Regulations—would require. In particular, we focus on how a treaty would provide opportunities to simultaneously expand reporting obligations, accelerate the sharing of scientific discoveries, and strengthen existing legal frameworks, all while addressing the most complex issues that global health governance currently faces.

Interplay between sickle cell anaemia and Plasmodium falciparum malaria
Ambrose Otau Talisuna, Umberto D'Alessandro

Difficult questions about long COVID in children
Maren Johanne Heilskov Rytter

Articles
Sickle cell anaemia and severe Plasmodium falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT)
Sophie Uyoga, et al.

Long COVID symptoms in SARS-CoV-2-positive children aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study
Selina Kikkenborg Berg, et al.

Summary
This two-paper Series focuses on recent advances and applications of regenerative medicine that could benefit paediatric patients. Innovations in genomic, stem-cell, and tissue-based technologies have created progress in disease modelling and new therapies for congenital and incurable paediatric diseases. Prenatal approaches present unique opportunities associated with substantial biotechnical, medical, and ethical obstacles. Maternal plasma fetal DNA analysis is increasingly adopted as a noninvasive prenatal screening or diagnostic test for chromosomal and monogenic disorders. The molecular basis for cell-free DNA detection stimulated the development of circulating tumour DNA testing for adult cancers. In-utero stem-cell, gene, gene-modified cell (and to a lesser extent, tissue-based) therapies have shown early clinical promise in a wide range of paediatric disorders. Fetal cells for postnatal treatment and artificial placenta for ex-utero fetal therapies are new frontiers in this exciting field.
Paediatric regenerative medicine

**Regenerative medicine: prenatal approaches**
Paolo de Coppi, et al.

**Paediatric regenerative medicine**

**Regenerative medicine: postnatal approaches**
Paul Kwong Hang Tam, et al.

**Lancet Digital Health**
Aug 2022 Volume 4 Number 8 e566-e626
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

**Lancet Global Health**
Aug 2022 Volume 10 Number 8 e1073-e1208
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

**Lancet Infectious Diseases**
Aug 2022 Volume 22 Number 8 p1091-1252, e207-e238
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

**Lancet Public Health**
Aug 2022 Volume 7 Number 8 e647-e724
https://www.thelancet.com/journals/lanpub/issue/current

**Viewpoint**
**From Health in All Policies to Health for All Policies**
Scott L Greer, et al.

**Summary**
Worldwide responses to the COVID-19 pandemic have shown that it is possible for politicians to come together across departmental boundaries. To this end, in many countries, heads of government and their health ministers work closely with all other ministries, departments, and sectors, including social affairs, internal affairs, foreign affairs, research and education, transport, agriculture, business, and state aid. In this Viewpoint, we build on the Health in All Policies approach by which the Sustainable Development Goals (SDGs) support intersectoral collaboration to promote health but argue that this relationship should be bidirectional and that health enables the attainment of other SDGs—Health for All Policies. We contend that strengthening health policies and improving health outcomes have major and tangible co-benefits for other sectors.

**Lancet Respiratory Medicine**
Aug 2022 Volume 10 Number 8 p725-810, e73-e77
Editorial

COVID-19 pandemic disturbs respiratory virus dynamics
The Lancet Respiratory Medicine

Articles

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial
Jing-Xin Li, et al., for the CanSino COVID-19 Study Group

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Fengcai Zhu, et al.

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
Rolando Ochoa-Azze, et al.

Maternal and Child Health Journal
Volume 26, issue 6, June 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-6
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 42 Issue 6, August 2022
http://mdm.sagepub.com/content/current
[New issue; No digest content identified]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 100, Issue 2 Pages: 315-616 June 2022
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Nature
https://www.nature.com/nature/volumes/607/issues/7920
Volume 608 Issue 7923, 18 August 2022
Research
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Biochemical and structural studies of the interactions between antibodies and spike proteins from SARS-CoV-2 Omicron subvariants indicate how these variants have evolved to escape antibody-mediated neutralization.
Yunlong Cao, Ayijiang Yisimayi, Xiaoliang Sunney Xie

Article  Open Access 17 Jun 2022

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Findings from a systematic antigenic analysis of these surging Omicron subvariants that this lineage of SARS-CoV-2 continues to evolve, successively yielding subvariants that are not only more transmissible but also more evasive to antibodies.
Qian Wang, Yicheng Guo, David D. Ho
Article Open Access 05 Jul 2022

Volume 608 Issue 7922, 11 August 2022

Editorial  09 Aug 2022
Preventive HIV drug shows urgent need for transparency on pricing
The drug cabotegravir could be a game-changer in the fight against HIV/AIDS — but we need to know why it costs so much.

Volume 608 Issue 7921, 4 August 2022

Editorial  03 Aug 2022
Get childhood immunizations back on track after COVID
The effects of the pandemic mean childhood vaccination rates are the lowest for a generation. There is a risk of preventable diseases resurfacing unless governments treat this as a priority.

Editorial  02 Aug 2022
How AlphaFold can realize AI’s full potential in structural biology
To make the most of artificial intelligence, data and software must be freely shared, and computational, theoretical and experimental researchers must work together closely.

Nature Biotechnology
Volume 40 Issue 8, August 2022
https://www.nature.com/nbt/volumes/40/issues/8
Editorial  03 Aug 2022
Increase vigilance against cyberattacks
The biotech sector must devote more resources to cybersecurity — especially those companies that are manufacturers of essential medical products.

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 21 Aug 2022)
[No new digest content identified]

Nature Genetics
Volume 54 Issue 8, August 2022
Supporting undiagnosed participants when clinical genomics studies end

Many large research initiatives have cumulatively enrolled thousands of patients with a range of complex medical issues but no clear genetic etiology. However, it is unclear how researchers, institutions and funders should manage the data and relationships with those participants who remain undiagnosed when these studies end. In this Comment, we outline the current literature relevant to post-study obligations in clinical genomics research and discuss the application of current guidelines to research with undiagnosed participants.
Meghan C. Halley, Euan A. Ashley, Holly K. Tabor

Nature Human Behaviour
Volume 6 Issue 8, August 2022

Science must respect the dignity and rights of all humans
New ethics guidance addresses potential harms for human population groups who do not participate in research but may be harmed by its publication.

Resilient government requires data science reform
Data has tremendous potential to build resilience in government. To realize this potential, we need a new, human-centred, distinctly public sector approach to data science and AI, in which these technologies do not just automate or turbocharge what humans can already do well, but rather do things that people cannot.
Ben D. MacArthur, Cosmina L. Dorobantu, Helen Z. Margetts

The supply and demand of news during COVID-19 and assessment of questionable sources production
Studying news supply and demand amidst the COVID-19 pandemic in Italy, Gravino and coauthors show that news production by unreliable sources is more sensitive to the public interest than reliable news.
Pietro Gravino, Giulio Prevedello, Vittorio Loreto
Article 23 May 2022

The impacts of remote learning in secondary education during the pandemic in Brazil
Using a differences-in-differences approach, Lichand et al. estimate the effects of remote learning in São Paulo, Brazil, during the pandemic. Their findings suggest that middle- and high-school students learned only 27.5% of the in-person equivalent and that dropout risk increased by 365%.
Guilherme Lichand, Carlos Alberto Doria, João Paulo Cossi Fernandes
Article Open Access 26 May 2022

Nature Medicine
Volume 28 Issue 8, August 2022

Comment 28 Jun 2022
How better pandemic and epidemic intelligence will prepare the world for future threats

A new approach to pandemic and epidemic intelligence is needed that includes modern approaches to surveillance and risk assessment, as well as improved trust and cooperation between stakeholders and society.
Oliver W. Morgan, Philip Abdelmalik, Chikwe Ihekweazu

Article  Open Access 16 Jun 2022
Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance

A model that predicts the effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants, before the acquisition of real-world effectiveness data, may help guide more rapid public health and research responses to new variants of concern.
Lirong Cao, Jingzhi Lou, Maggie Haitian Wang

Nature Reviews Genetics
Volume 23 Issue 8, August 2022
https://www.nature.com/nrg/volumes/23/issues/8

Comment  10 Jun 2022
Unpacking race and ethnicity in African genomics research

In this Comment, the authors highlight caveats about using African ethnicities as population categories in genomics research and emphasize the need for an Africa-oriented humanities research agenda to inform genomics research.
Henri-Michel Yéré, Mavis Machirori, Jantina De Vries

Nature Reviews Immunology
Volume 22 Issue 7, July 2022
https://www.nature.com/nri/volumes/22/issues/7
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 21 Issue 8, August 2022
https://www.nature.com/nrd/volumes/21/issues/8

Comment  27 Jun 2022
Advancing innovative clinical trials to efficiently deliver medicines to patients

Complex innovative designs in clinical trials have the potential to increase efficiency and lower the cost of drug development, improving patient access to therapies. This article highlights designs and approaches based on a meeting linked to an ongoing FDA pilot program in the field.
Robert A. Beckman, Fanni Natanegara, Debra Michaels

New England Journal of Medicine
https://www.nejm.org/toc/nejm/medical-journal
August 18, 2022  Vol. 387 No. 7
Perspective
**Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations**
A. Sherwat, J.T. Brooks, D. Birnkrant, and P. Kim

---

**Original Articles**

**Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19**
C.T. Bramante and Other

---

**Editorials**

**Time to Stop Using Ineffective Covid-19 Drugs**
S.S. Abdool Karim and N. Devnarain

---

**Audio Interview: Responding to Monkeypox**
E.J. Rubin, L.R. Baden, D.C. Daskalakis, and S. Morrissey

---

**August 11, 2022  Vol. 387 No. 6**

**Perspective**

**Considering Race and Ethnicity in Covid Risk Assessments — Legal Concerns and Possible Solutions**
T.S. Jost

---

**Understanding Covid Vaccine Efficacy over Time — Bridging a Gap Between Public Health and Health**
CareI. Kohane and G.S. Omenn

---

**Bringing Sickle-Cell Treatments to Children in Sub-Saharan Africa**
A.E. Zhou and M.A. Travassos

---

**Original Article**

**Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age**
S.H.X. Tan and Others

---

**August 4, 2022  Vol. 387 No. 5**

**Editorials**

**Monoclonal Antibodies — A Different Approach to Combat Malaria**
J.P. Daily

---

**Science behind the Study: Monoclonal Antibodies for Malaria**
T. Wells and C. Donini

---

**Audio Interview: Updated Covid-19 Vaccines and a Look at Monkeypox**
E.J. Rubin, L.R. Baden, and S. Morrissey

---

**npj Vaccines**

[https://www.nature.com/npjvaccines/](https://www.nature.com/npjvaccines/)
[Accessed 21 Aug 2022]

**Current status of monkeypox vaccines**
Marion F. Gruber
**Understanding drivers of vaccine hesitancy among pregnant women in Nigeria: A longitudinal study**
Gbadebo Collins Adeyanju, Philipp Sprengholz, Cornelia Betsch
Article Open Access 17 Aug 2022

**Affordable SARS-CoV-2 protein vaccines for the pandemic endgame**
James A. Triccas, Joeri Kint, Florian M. Wurm
Comment Open Access 02 Aug 2022

**Pediatrics**
Volume 150, Issue 2  August 2022
https://publications.aap.org/pediatrics/issue/150/2

**Articles**
**Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years**
Anne M. Hause, PhD, MSPH; David K. Shay, MD, MPH; Nicola P. Klein, MD, PhD; Winston E. Abara, MD; James Baggs, PhD.

**Coaching and Communication Training for HPV Vaccination: A Cluster Randomized Trial**
Melissa B. Gilkey, PhD; Brigid K. Grabert, PhD, JD; Jennifer Heisler-MacKinnon, MPH; Adam Bjork, PhD; Marcella H. Boynton, PhD.

**Commentaries**
**COVID-19 Vaccines: Safe and Effective in Children Aged 5 to 11 Years**
Sara E. Oliver, MD, MSPH; Megan Wallace, DrPH, MPH; Ruth Link-Gelles, PhD, MPH

**PharmacoEconomics**
Volume 40, issue 8, August 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-8
[New issue; No digest content identified]

**PLoS Biology**
https://journals.plos.org/plosbiology/
(Accessed 21 Aug 2022)

**Consensus View**
**Designing and implementing a research integrity promotion plan: Recommendations for research funders**
Serge P. J. M. Horbach, Lex M. Bouter, George Gaskell, Maura Hiney, Panagiotis Kavouras, Niels Mejlaaard, Nick Allum, Noémie Aubert Bonn, Anna-Kathrine Bendtsen, Costas A. Charitidis, Nik Claesen, Kris Dierickx, Anna Domaradzka, Andrea Reyes Elizondo, Nicole Föger, Wolfgang Kaltenbrunner, Teodora Konach, Krishna Labib, Ana Marušić, Daniel Pizzolato, Tine Ravn, Rea Roje, Mads P. Sørensen, Borana Tarej, Giuseppe A. Veltri, Joeri K. Tijdink
| published 19 Aug 2022 PLOS Biology
https://doi.org/10.1371/journal.pbio.3001773
Abstract
Various stakeholders in science have put research integrity high on their agenda. Among them, research funders are prominently placed to foster research integrity by requiring that the organizations and individual researchers they support make an explicit commitment to research integrity. Moreover, funders need to adopt appropriate research integrity practices themselves. To facilitate this, we recommend that funders develop and implement a Research Integrity Promotion Plan (RIPP). This Consensus View offers a range of examples of how funders are already promoting research integrity, distills 6 core topics that funders should cover in a RIPP, and provides guidelines on how to develop and implement a RIPP. We believe that the 6 core topics we put forward will guide funders towards strengthening research integrity policy in their organization and guide the researchers and research organizations they fund.

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 21 Aug 2022)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 21 Aug 2022)
Universal healthcare coverage and health service delivery before and during the COVID-19 pandemic: A difference-in-difference study of childhood immunization coverage from 195 countries
Sooyoung Kim, Tyler Y. Headley, Yesim Tozan
Research Article | published 16 Aug 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004060

Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system–based cross-sectional study
Inmaculada Hernandez, Sean Dickson, Shangbin Tang, Nico Gabriel, Lucas A. Berenbrok, Jingchuan Guo
Research Article | published 28 Jul 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004069

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 21 Aug 2022)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 21 Aug 2022]
Assessment of COVID-19 vaccination-related medical waste management practices in Bangladesh
Facilitators and barriers to COVID-19 vaccine uptake among women in two regions of Ghana: A qualitative study
Grace Frempong Afrifa-Anane, Reuben Tete Larbi, Bright Addo, Martin Wiredu Agyekum, Frank Kyei-Arthur, Margaret Appiah, Clara Opoku Agyemang, Ignatius Great Sakada
Research Article | published 17 Aug 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0272876

COVID-19 vaccination uptake in 441 socially and ethnically diverse pregnant women
Fatima Husain, Veronica R. Powys, Eleanor White, Roxanne Jones, Lucy P. Goldsmith, Paul T. Heath, Pippa Oakeshott, Mohammad Sharif Razai
Research Article | published 17 Aug 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0271834

Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines—Early experience with vaccine rollout in a multi-site healthcare system
Sarah Al-Obaydi, Eileen Hennrikus, Nazar Mohammad, Erik B. Lehman, Abhishek Thakur, Taha Al-Shaikhly
Research Article | published 05 Aug 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0272691

Assessing the influence of French vaccine critics during the two first years of the COVID-19 pandemic
Mauro Faccin, Floriana Gargiulo, Laëtitia Atlani-Duault, Jeremy K. Ward
Research Article | published 04 Aug 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0271157

Comparative analysis of pre-Covid19 child immunization rates across 30 European countries and identification of underlying positive societal and system influences
Marco Cellini, Fabrizio Pecoraro, Michael Rigby, Daniela Luzi
Research Article | published 03 Aug 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0271290

PloS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 21 Aug 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
July 26, 2022 | vol. 119 | no. 30
https://www.pnas.org/toc/pnas/119/30
Perspective July 12, 2022
Why are people antiscience, and what can we do about it?
From vaccination refusal to climate change denial, antiscience views are threatening humanity. When different individuals are provided with the same piece of scientific evidence, why do some accept whereas others dismiss it? Building on various emerging ...
Aviva Philipp-Muller, Spike W. S. Lee and Richard E. Petty
---

**Public Health Ethics**  
Volume 15, Issue 1, April 2022  
[http://phe.oxfordjournals.org/content/current](http://phe.oxfordjournals.org/content/current)  
[Reviewed earlier]  

**Public Health Reports**  
Volume 137 Issue 3, May/June 2022  
[https://journals.sagepub.com/toc/phrg/137/3](https://journals.sagepub.com/toc/phrg/137/3)  
[Reviewed earlier]  

**Qualitative Health Research**  
Volume 32 Issue 8-9, July 2022  
[https://journals.sagepub.com/toc/qhra/current](https://journals.sagepub.com/toc/qhra/current)  
[New issue; No digest content identified]  

**Research Ethics**  
Volume 18 Issue 3, July 2022  
[http://journals.sagepub.com/toc/reab/current](http://journals.sagepub.com/toc/reab/current)  
[Reviewed earlier]  

**Reproductive Health**  
[http://www.reproductive-health-journal.com/content](http://www.reproductive-health-journal.com/content)  
[Accessed 21 Aug 2022]  
[No new digest content identified]  

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**  
[https://www.paho.org/journal/en](https://www.paho.org/journal/en)  
*Selected Articles*  
19 Aug 2022  
**Surveillance of adverse events associated with 145 000 doses of COVID-19 vaccines in a Brazilian municipality**  
Brief communication | English |  

19 Aug 2022  
**Control of cervical cancer in the primary care setting in South American countries: systematic review**  
Review | Portuguese |  

19 Aug 2022  
---
Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome
Original research | English |

17 Aug 2022
Emergency Preparedness: A Shared Effort
Editorial | English |

17 Aug 2022
Health Emergency Preparedness and Response Capacity in Latin America and the Caribbean
Editorial | English |

17 Aug 2022
COVID-19 in Colombia and Venezuela: two sides of the coin
Editorial | English |

17 Aug 2022
The Fight Against COVID-19: A Perspective From Latin America and the Caribbean
Editorial | English |

17 Aug 2022
Lessons From the COVID-19 Pandemic in Latin America: Vulnerability Leading to More Vulnerability
Editorial | English |

17 Aug 2022
How We Faced the Challenge of COVID-19 in Antioquia, Colombia
Editorial | English |

17 Aug 2022
Contributions of the new framework for essential public health functions to addressing the COVID-19 pandemic
Opinion and analysis | English |

Risk Analysis
Volume 42, Issue 6 Pages: 1149-1364 June 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Bayesian Networks for Risk Analysis and Decision Support
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 21 Aug 2022]
Original Research
Impact of COVID-19 on Health Seeking Behavior of Patients with Chronic Disease at Public Hospitals in Jimma Zone, South West Ethiopia
Awel S, Ahmed I, Tilahun D, Tegenu K
Published Date: 1 August 2022

Science
https://www.science.org/toc/science/current
Volume 377 | Issue 6608 | 19 Aug 2022
Editorial
Rethinking the retraction process
BY H. Holden Thorp
18 Aug 2022

Feature
Anywhere but here
BY Jon Cohen
18 Aug 2022: 805-809
China now insists the pandemic didn’t start within its borders. Its scientists are publishing a flurry of papers pointing the finger elsewhere

Volume 377 | Issue 6607 | 12 Aug 2022
[No digest content identified]

Volume 377 | Issue 6606 | 5 Aug 2022
Policy Forum
Transparency practices at the FDA: A barrier to global health
BY Murray M. Lumpkin, Margaret A. Hamburg, William B. Schultz, Joshua M. Sharfstein
04 Aug 2022: 572-574
Data sharing among regulators must be “business as usual”

Science and Engineering Ethics
Volume 28, issue 4, August 2022
https://link.springer.com/journal/11948/volumes-and-issues/28-4
[New issue; No digest content identified]

Science Translational Medicine
Volume 14| Issue 658 | 17 Aug 2022
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Social Science & Medicine
Volume 302  June 2022
[Reviewed earlier]
Evaluation of efficacy and safety of intradermal delivery of vaccines through microneedle(s) in human beings: a protocol for a systematic review

Microneedles are defined as micron-sized projections with an insertion length ranging from 20 to 1500 μm and an external diameter up to 300 μm. Medications administered through microneedles diffuse through the...

Authors: Ishumeet Kaur Bajwa, Navneet Kaur, Jeanne M. Dsouza and Joseph L. Mathew
Citation: Systematic Reviews 2022 11:170
Content type: Protocol Published on: 13 August 2022

Sexual and reproductive health services during outbreaks, epidemics, and pandemics in sub-Saharan Africa: a literature scoping review

The COVID-19 pandemic could worsen adolescent sexual and reproductive health (ASRH). We sought evidence on the indirect impacts of previous infectious disease epidemics and the current COVID-19 pandemic on the...

Authors: Mwila Ng’andu, Aldina Mesic, Jake Pry, Chanda Mwamba, Florence Roff, Jenala Chipungu, Yael Azgad and Anjali Sharma
Citation: Systematic Reviews 2022 11:161
Content type: Systematic review update Published on: 9 August 2022

The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review

Tuberculosis (TB) is considered one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent. Multidrug-resistant (MDR) TB can affect people of all age groups, incl...

Authors: Sheetal Harichander, Ebenezer Wiafe, Kofi Boamah Mensah, Varsha Bangalee and Frasia Oosthuizen
Citation: Systematic Reviews 2022 11:157
Content type: Research Published on: 4 August 2022

Theoretical Medicine and Bioethics
Volume 43, issue 2-3, June 2022
[New issue; No digest content identified]

Travel Medicine and Infectious Diseases
Volume 48  July–August 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 7  Pages: i-iv, 603-654  July 2022
**Technology transfer programme for influenza vaccines – Lessons from the past to inform the future**

Christopher Chadwick, Martin Friede, Ann Moen, Claudia Nannei, Erin Sparrow

Pages 4673-4675

**COVID-19 vaccination in pregnant women in Sweden and Norway**

Anne K. Örtqvist, Elisabeth Dahlqwist, Maria C. Magnus, Rickard Ljung, ... Olof Stephansson

Pages 4686-4692

**Trust in the public health system as a source of information on vaccination matters most when environments are supportive**

Sophie Lohmann, Dolores Albarracín

Pages 4693-4699

**A national survey of COVID-19 vaccine acceptance in Nigeria**

Ahmad Ibrahim Al-Mustapha, Ochulor Okechukwu, Ademola Olayinka, Oyeniyi Rasheed Muhammed, ... Victoria Olusola Adetunji

Pages 4726-4731

**Influenza vaccination hesitancy and its determinants among elderly in China: A national cross-sectional study**

Zhiyuan Hou, Jia Guo, Xiaozhen Lai, Haijun Zhang, ... Hai Fang

Pages 4806-4815

**Radio public service announcements to promote vaccinations for older adults: Effects of framing and distraction**

Anne Reinhardt, Constanze Rossmann, Elena Engel

Pages 4864-4871

**The impact of personal coaching on influenza vaccination among healthcare workers before and during COVID-19 pandemic**

Shuk-Ching Wong, Veronica Wing-Man Chan, Germaine Kit Ming Lam, Lithia Lai-Ha Yuen, ... Vincent Chi-Chung Cheng

Pages 4905-4910
Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study
Benjamin Wyplosz, Jérôme Fernandes, Ariane Sultan, Nicolas Roche, ... Gwenaël Goussiaume
Pages 4911-4921

Value in Health
August 2022 Volume 25 Issue 8 p1257-1462
https://www.valueinhealthjournal.com/current

THEMED SECTION: COVID-19

Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
Stijntje W. Dijk, et al.
Published online: April 27, 2022
p1268-1280

Public Preferences for Policies to Promote COVID-19 Vaccination Uptake: A Discrete Choice Experiment in The Netherlands
Niek Mouter, et al.
Published online: May 05, 2022
p1290-1297

SYSTEMATIC LITERATURE REVIEW

Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults
Desmond Loong, et al.
Published online: June 02, 2022
p1439-1458

:: Pre-Print Servers ::

Gates Open Research
https://gatesopenresearch.org/browse/articles

Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma
[version 1; peer review: awaiting peer review]
Ignacio Esteban, María Teresa Panighetti, Fernando P. Polack
Peer Reviewers Invited
Funder
Bill and Melinda Gates Foundation
PUBLISHED 15 Aug 2022
Systematic Review metrics AWAITING PEER REVIEW

**Systematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children** [version 1; peer review: awaiting peer review]

Angela M. Bagattini, Michelle M. Quarti, Martha S. Martinez-Silveira, Gabriela Policena, Lara E. Coelho, Paula M. Luz, Louise B. Russell, Cristiana M. Toscano

Peer Reviewers Invited

Funder

AB was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil

PUBLISHED 05 Aug 2022

medRxiv

https://www.medrxiv.org/content/about-medrxiv

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Selected Research

**Effectiveness of fourth dose COVID-19 vaccine against the Omicron variant compared to no vaccination**

Jessie Zeng, Joshua Szanyi, Tony Blakely

medRxiv 2022.08.17.22278807; doi: https://doi.org/10.1101/2022.08.17.22278807

**Detection of Monkeypox virus DNA in the wastewater of an airport in Rome, Italy: expanding environmental surveillance to emerging threats**

Giuseppina La Rosa, Pamela Mancini, Carolina Veneri, Giusy Bonanno Ferraro, Luca Lucentini, Marcello Iaconelli, Elisabetta Suffredini

medRxiv 2022.08.18.22278932; doi: https://doi.org/10.1101/2022.08.18.22278932

**First detection of Monkeypox virus genome in sewersheds in France**

SEBASTIEN WURTZER, Morgane Levert, Eloise Dhenain, Mickael Boni, Jean-Nicolas Tournier, Nicolas Londinsky, Agnes Lefranc, Scientic interest group Obepine, Olivier Ferraris, Laurent Moulin

medRxiv 2022.08.18.22278938; doi: https://doi.org/10.1101/2022.08.18.22278938

**Maximizing the impact of limited vaccine supply under different epidemic conditions: a two-city monkeypox modelling analysis**

Jesse Knight, Darrell Tan, Sharmistha Mishra

medRxiv 2022.08.18.22278949; doi: https://doi.org/10.1101/2022.08.18.22278949

**The effect of COVID-19 vaccination and booster on maternal-fetal outcomes: a retrospective multicenter cohort study**

Samantha N. Piekos, Yeon Mi Hwang, Ryan T. Roper, Tanya Sorensen, Nathan D. Price, Leroy Hood, Jennifer J. Hadlock

medRxiv 2022.08.12.22278727; doi: https://doi.org/10.1101/2022.08.12.22278727 Revision
The role of vaccination and public awareness in medium-term forecasts of monkeypox incidence in the United Kingdom
SPC Brand, M Cavallaro, J Hilton, LM Guzman-Rincon, T House, MJ Keeling, DJ Nokes
medRxiv 2022.08.15.22278788; doi: https://doi.org/10.1101/2022.08.15.22278788

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis
Kiesha Prem, Yoon Hong Choi, Élodie Bénard, Emily A Burger, Liza Hadley, Jean-François Laprise, Mary Caroline Regan, Mélanie Drolet, Stephen Sy, Kaja Abbas, Allison Portnoy, Jane J Kim, Marc Brisson, Mark Jit
medRxiv 2021.02.08.21251186; doi: https://doi.org/10.1101/2021.02.08.21251186 Revision

COVID-19 risk perception and vaccine acceptance in individuals with chronic disease
Brianna A. Smith, Emily E. Ricotta, Jennifer L. Kwan, Nicholas G. Evans
medRxiv 2021.03.17.21253760; doi: https://doi.org/10.1101/2021.03.17.21253760 Revision

Modelling vaccination and control strategies of outbreaks of monkeypox at gatherings
Pei Yuan, Yi Tan, Liu Yang, Elena Aruffo, Nicholas H. Ogden, Jacques Bélair, Julien Arino, Jane Heffernan, James Watmough, Hélène Carabin, Huaping Zhu
medRxiv 2022.08.12.22278724; doi: https://doi.org/10.1101/2022.08.12.22278724

Estimating the future global dose demand for Measles-Rubella microarray patches
Melissa Ko, Stefano Malvoti, Thomas Cherian, Carsten Mantel, Robin Biellik, Courtney Jarrahian, Marion Menozzi-Arnaud, Jean-Pierre Amorij, Hans Christiansen, Mark Papania, Martin I. Meltzer, Balcha Girma Masresha, Desiree Pastor, David N. Durrheim, Birgitte Giersing, Mateusz Hasso-Agopsowicz
medRxiv 2022.08.11.22278665; doi: https://doi.org/10.1101/2022.08.11.22278665

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 21 Aug 2022]
No new digest content identified.

Wellcome Open Research [to 21 Aug 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 21 Aug 2022]
Selected Research
Research Article metrics Awaiting Peer Review
Effectiveness of seasonal malaria chemoprevention administered in a mass campaign in the Kedougou region of Senegal in 2016: a case-control study [version 1; peer review: awaiting peer review]
Isaac Akhenaton Manga, Fassiatou Tairou, Amadou Seck, EKoue Kouevidjin, Khadime Sylla, Doudou Sow, Alioune Babara Gueye, Mady Ba, Magatte Ndiaye, Roger Clément Kouly Tine, Omar Gaye, Babacar Faye, Jean Louis Abdourahim Ndiaye
Peer Reviewers Invited
Funders
Wellcome
Case Report: Adult Onset Still’s Disease after vaccination against Covid-19

Ujjwol Risal, Anup Subedee, Raju Pangeni, Rakshya Pandey, Suravi Pandey, Sudeep Adhikari, Buddha Basnyat

Peer Reviewers Amita Aggarwal; Sankha S. Chakrabarti

Funder

Wellcome Trust

LATEST VERSION PUBLISHED 15 Aug 2022

Think Tanks

Brookings  [to 21 Aug 2022]
http://www.brookings.edu/
Accessed 21 Aug 2022
Latest Research
Technology & Innovation
The roadmap to telehealth efficacy: Care, health, and digital equities
Nicol Turner Lee, Niam Yaraghi, and Samantha Lai
Monday, July 25, 2022

Center for Global Development  [to 25 Jun 2022]
https://www.cgdev.org/
All Research [Selected]
[No new digest content identified]

Chatham House  [to 21 Aug 2022]
https://www.chathamhouse.org/
The World Today Now is the moment to launch an African vaccine industry
The continent plans to make 60 per cent of its vaccines by 2040. After the failure of the world to help in the pandemic, it’s high time, says Ngozi Erondu.
3 August 2022

CSIS  [to 21 Aug 2022]
https://www.csis.org/
Selected Reports/Content
[No new digest content identified]
Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 21 Aug 2022
Publications
No new digest content identified.

ODI [Overseas Development Institute] [to 21 Aug 2022]
Publications
No new digest content identified.

Pew Research Center [to 21 Aug 2022]
https://www.pewresearch.org/
Latest Publications
Short Read | Aug 18, 2022
Many Americans say they have shifted their priorities around health and social activities during COVID-19
We asked respondents to describe in their own words what rose and fell in importance to them during the pandemic. Here are some of the key themes that emerged.

Report | Aug 11, 2022
Partisanship Colors Views of COVID-19 Handling Across Advanced Economies
A median of 68% across 19 countries think their country has done a good job dealing with the coronavirus outbreak, with majorities saying this in every country surveyed except Japan. However, most also believe the pandemic has created greater divisions in their societies and exposed weaknesses in their political systems – and these view are especially common in the U.S.

Rand [to 21 Aug 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Journal Article
Belief Correlations with Parental Vaccine Hesitancy: Results from a National Survey
We conducted a nationally representative survey of parents' beliefs and self-reported behaviors regarding childhood vaccinations.
Aug 17, 2022
Luke J. Matthews, Sarah A. Nowak, Courtney A. Gidengil, Christine Chen, Joe Stubbersfield, Jamshid J. Tehrani, Andrew M. Parker

Journal Article
Association Among Trust in Health Care Providers, Friends, and Family, and Vaccine Hesitancy
Parents who are hesitant to vaccinate their children trust various types of individuals along different dimensions of trust.
Aug 17, 2022
Sarah A. Nowak, Courtney A. Gidengil, Andrew M. Parker, Luke J. Matthews

Urban Institute  [to 21 Aug 2022]
https://www.urban.org/publications
New Research Publications
No new digest content identified.

World Economic Forum  [to 21 Aug 2022]
https://www.weforum.org/press/
Media
No new digest content identified

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).
Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *
* * * *